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DEFINITIONS OF KEY TERMS 
 
Anatomic Therapeutic Class (ATC) – is a classification system that uses active 
pharmaceutical ingredients to classify medicines into a system consisting of five different 
levels 
Antibiotics – substances which inhibit the growth of bacteria or directly destroy the bacteria 
with the aim of resolving infection 
Antibiotic resistance – when bacteria continues to grow in the presence of antibiotic substance 
which would ordinarily inhibit its growth or destroy it this will mean that the bacteria has 
become resistant to the antibiotic substance 
Antimicrobials – substances which destroying or inhibit the growth of microorganisms which 
include antibiotics, antivirals, antiprotozoals and antifungals 
Antimicrobial resistance – when microorganisms continue to grow in the presence of 
antimicrobial substance which would ordinarily inhibit its growth or destroy it this will mean 
that the microorganism has become resistant to the antibiotic substance 
Daily Defined Dose – is the assumed average maintenance dose per day for a drug used for its 
main indication in adults  
Daily Defined Dose per 1000 inhabitants per day (DID) – represents the proportion of the 
selected population using a particular medicine per day 
Namibia Essential Medicines List (NEMList) – The NEMList is a list of essential medicines 
which can be ordered, stored and prescribed at public sector health facilities in Namibia  
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ABSTRACT 
Background Antibiotic resistance is a phenomenon that occurs naturally and is accelerated 
by use. There have been no studies looking at trends in antibiotic consumption in the public 
health sector in Namibia, which provides services to 85% of the population. 
Aim This study described the pattern of antibiotic consumption in the Namibian public health 
sector based on distribution of antibiotics from Central Medical Stores (CMS) to the 13 regions 
in the country.  
Methodology Antibiotic consumption data from distribution records at the Central Medical 
Store (CMS), public health sector wholesaler, between 1 January 2010 and 31 December 2016 
was collated and analysed to describe trends and usage patterns in the public health sector of 
Namibia. For the purpose of this study DDD per 1000 inhabitants per day (DID) was used as 
an indicator so as to be comparable with previously conducted studies. DIDs provide 
information about the proportion of the selected population using a particular medicine per day. 
The World Health Organization (WHO) recommended anatomical therapeutic classification 
(ATC)/daily defined dose (DDD) methodology be used to analyse the data and evaluate the 
consumption. Data was presented using stacked bar charts to demonstrate the variation in 
consumption by ATC classes in each region and over time. 
Ethical Considerations Ethical clearance was obtained from the University of the Western 
Cape Biomedical Research Ethics Committee and permission to access and use the data was 
provided by the Ministry of Health and Social Services. As the study used retrospective data 
from the CMS there were no direct interactions with patients or health services staff. 
Results and Discussion A total of 227,068 items were issued from the CMS and multi-regional 
medical stores (MRMS) to the public health facilities in Namibia, during the period under 
review. Of those items 41,025 (18%) were antibiotics as defined by anatomical therapeutic 
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classification (ATC) class J01 of the World Health Organization (WHO) classification. 
Namibia’s antibiotic consumption for the public sector increased by 13.2% from 38.31 DID in 
2010 to 43.37 DID in 2016, with an average of 41.81 DID during the study period. The 
antibiotic class with the highest consumption in the public sector was sulphonamide and 
trimethoprim which made up 51% of the total antibiotic consumption in 2010 and again in 
2016. In the sulphonamide and trimethoprim class the co-trimoxazole 80 + 400 mg tablets were 
the highest consumed item during the period under review, making co-trimoxazole 80 + 400 
mg tablets the highest consumed antibiotic formulation in the Namibian public sector. Beta 
lactam penicillins were the second highest antibiotic class. Among the regions, the lowest 
consumption was found in Ohangwena region which contributed 6% to the national total, with 
Zambezi having the highest consumption making up about 13% of national total. The largest 
increase in consumption within the regions was for Zambezi region which increased by 73% 
from 2010 to 2016; this increase was followed by 57% in Ohangwena region and 47% in 
Omaheke. 
Conclusion The total national antibiotic consumption for Namibia is classified as high 
according to the European Surveillance of Antimicrobial Consumption (ESAC) 2010 
classification system. The high consumption of sulphonamides and trimethoprim was 
attributed to the wide use of co-trimoxazole prophylaxis for HIV/AIDS related opportunistic 
infections. It is therefore imperative that one of the consumption reduction strategies be 
targeted at reducing the burden of HIV/AIDS with the aim of reducing the requirement for the 
antibiotic co-trimoxazole. The high consumption of beta lactam penicillins class is ascribed to 
the fact that beta lactam penicillins are first line treatment in the majority of the cases needing 
antibiotics in Namibia according to the national Standard Treatment Guidelines. 
http://etd.uwc.ac.za/
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Recommendations Several recommendations have been formulated. They include: That this 
study be carried out on an annual basis by each Regional Pharmacist in each region in Namibia. 
The differences in consumption rates between regions should be further investigated in order 
to determine the cause of the differences. It was also recommended that all countries use this 
methodology to determine the consumption of antibiotics with the aim of gathering data to 
inform interventions to reduce or rationalise the use of antibiotics.  
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CHAPTER 1: INTRODUCTION  
 
1.1 Introduction 
Antibiotic resistance is a phenomenon that occurs naturally, however it is accelerated by 
overuse or misuse of antibiotics (Centre for Disease Dynamics, Economics & Policy, 2015, 
2009; Goossens, 2009; Pereko, et al., 2016; Santa-Ana-Tellez, et al., 2015). This means that 
the larger the volume of antibiotics used the higher the risk of resistance developing. This is an 
issue of growing concern for all countries including Namibia and others in Sub-Saharan Africa. 
Evidence of resistance to antibiotics from the Namibian Institute for Pathology (NIP) indicates 
that there is an increase in drug resistance in humans in Namibia (MoHSS Namibia, 2017). 
One of the concerns highlighted by the NIP database is the significant resistance to amoxicillin 
which is currently the first line treatment for most bacterial infections as per National Standard 
Treatment Guidelines (STGs). However, insufficiencies in surveillance of drug resistance 
hampers the process required to understand the challenges and magnitude of issues related to 
antimicrobial resistance (AMR). In addition, a study conducted on antibiotic usage in the 
private health sector revealed an increase in the use of antibiotics which was disproportionate 
to the increase in the population size (Pereko, et al., 2016). The situation in the public health 
sector, which provides care to 85% of population, is unknown (MoHSS, 2014). 
 
The Centre for Disease Dynamics, Economics & Policy (2015) claims that increased use can 
also be attributed to rising income levels which provides increased financial means to access 
antibiotics as well as the increase of antibiotic use in aqua- and agriculture. This is due to 
increased demand for animal production which leads producers to use antibiotics for growth 
enhancement (Centre for Disease Dynamics, Economics & Policy, 2015).  
 
Resistance has six main causative pathways (Yap, 2013; WHO, 2017). 
These include: 
 over-prescribing,  
 under-dosing,  
 non-therapeutic and sub-therapeutic use of antibiotics in livestock and aquaculture for 
the purposes of metaphylaxis, prophylaxis as well as growth enhancement,  
 poor infection control in hospitals which allows for the spread of ‘superbugs” from 
patient to patient as nosocomial infections,  
http://etd.uwc.ac.za/
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 lack of hygiene coupled with poor sanitation among the general public which leads to 
infections that require treatment with antibiotics further increasing the consumption of 
antibiotics  
 lag in discovery and development of new antibiotic classes (Santa-Ana-Tellez, et al., 
2015).  
 
1.2 Problem Statement  
Antimicrobial resistance negatively impacts health outcomes and health care costs, driven by 
the fact that patients with resistant strains are likely to be hospitalized for longer and that the 
medicines used to treat resistant strains are more expensive than those used to treat susceptible 
strains (Mohulatsi, 2016). There is also the risk of reversing the gains made possible by the 
effective treatment of previously curable infections. There is also strong evidence that high 
consumption of antibiotics translates to high levels of resistance (Wirtz, et al., 2010; Yap, 2013; 
Pereko, et al., 2015; Centre for Disease Dynamics, Economics & Policy, 2015; Pereko, et al., 
2016). 
 
There is evidence of growing resistance to antimicrobials used in the public sector of Namibia 
(Kibuule, et al., 2017). Resistance to antimicrobials used in the treatment of urinary tract 
infections (Mengistu, et al., 2014) as well as meningitis (Mengistu, et al., 2013) prompted a 
change in treatment protocols in Namibia following analysis of antimicrobial sensitivity data 
that showed growing resistance to the recommended first line therapy. Pereko, et al., (2016) 
analysed utilization of antibiotics in the Namibian private health sector, however, there have 
been no studies analysing trends in antibiotic consumption for the public sector which provides 
health services to 85% of the population of Namibia (MoHSS, 2014). This study addressed this 
data gap by analysing antibiotic consumption in the public health sector, disaggregated by 
region and over time.  
 
1.3 Study Setting 
Namibia is a country in south-western Africa with an area of about 824,000 square kilometres 
and a population of 2,113,077 in 2011 (MoHSS Namibia, 2013). The public health sector is 
divided into 13 Regional Health Directorates which oversee service delivery to 34 health 
districts. Public health services are provided through one national referral hospital, four 
intermediate hospitals, 30 district hospitals, 44 health centres, and 269 clinics including mission 
http://etd.uwc.ac.za/
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hospitals. Due to the vastness of the country, the sparse distribution of the population, and the 
lack of access to permanent health facilities in some communities, outreach (mobile clinic) 
services are provided at about 1,150 outreach points across the country (MoHSS Namibia, 
2013). The Namibian public health system serves about 85% of the total population with the 
rest being catered for by the private sector (MoHSS, 2014).  
 
The Namibian Medicines Regulatory Authority (NMRA) is the statutory body that controls 
medicines intended for humans and animals in both the public and private sectors. A pharmacist 
or other pharmacy staff may not sell antibiotics without a written prescription from a 
registered/licensed doctor or veterinarian (MoHSS Namibia, 2017). In line with the World 
Health Organisation (WHO) recommendations, Namibia’s first Essential Medicines List 
(NEMList) was developed in 1995. It was developed and updated through an evidence-based 
process conducted by the National Essential Medicines List Committee (MoHSS, 2016). 
Medicines are classified according to the level of the health care system where they should be 
available at and may be prescribed at, in line with the Namibian Standard Treatment Guidelines 
(STGs) (MoHSS, 2016). This classifications means that some medicines are available at all 
levels of care whilst some are only available at district-, intermediate and tertiary health care 
hospitals see Appendix 2. The guidelines indicate the treatment protocols to be followed in the 
country and guide the use of the medicines which are in the NEMList. These guidelines were 
launched in 2011 and they are the same for all regions. They have not been revised since 2011. 
 
Public sector medicines are procured by the government tender board and distributed to 
hospitals every six weeks via the Central Medical Stores (CMS). Distribution is via the pull 
method in which health facility staff determine their needs based on previous consumption data 
and place orders with their supplier. The CMS Distribution Network is depicted in Appendix 
1 for easy reference. Medicines are procured and distributed to the different health facility 
levels according to their classification in the NEMList (MoHSS, 2016) see Appendix 2.  
 
1.4 Purpose 
The purpose of this study was to describe the patterns of antibiotic consumption in the 
Namibian public health sector over seven years, between 2010 and 2016, desegregated by 
region, antibiotic class and antibiotic. This study helped identify regions where the rate of 
consumption of antibiotics per person was changing and those where consumption was stable. 
http://etd.uwc.ac.za/
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In addition, the pattern of antibiotic use by class of antibiotic was be characterized. This 
information serves as baseline data for measuring the impact of Namibia’s soon to be finalized 
National Action Plan on Antimicrobial Resistance (Namibia MoHSS, 2017) and for 
interventions to be developed and implemented through the newly revived antimicrobial 
stewardship programme. This study highlighted some of the key problem areas of antibiotic 
use, including areas for further investigation, which will guide future interventions. 
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CHAPTER 2: LITERATURE REVIEW  
 
2.1 Global 
The world’s antibiotic consumption increased by 30% from 50 billion to 70 billion units 
between the years 2000 to 2010 with the highest increase reported in lower middle-income 
countries (Center for Disease Dynamics, Economics & Policy, 2015). According to Klein, et 
al., (2018) global antibiotic consumption increased by 39% between 2000 and 2015 from 11.3 
to 15.7 DID. This is a concern since an increase in use is associated with an increase in 
resistance. There are two major contributors to this global increase in consumption. One is the 
increasing access to antibiotics through increased income which is evidenced by the higher 
consumption noted in higher income countries. The second is the increasing demand for animal 
proteins which leads to high use of antibiotics in agriculture to optimize production (Centre for 
Disease Dynamics, Economics & Policy, 2015). 
 
A study looking at antibiotic usage trends in Latin American countries found there to be 
substantial variation in antibiotic usage patterns between the countries studied (Wirtz, et al., 
2010). In this study consumption was measured using the unit defined daily dose per 1 000 
inhabitants per day (DID). The average utilization among the eight countries included 
increased from 10.92 DID in 1997 to 11.99 in 2007 with Venezuela having a high of 15.99 
DID in 2007 and Uruguay a low of 3.93 DID in 1997 (Wirtz, et al., 2010). These differences 
could be ascribed to socioeconomic factors such as economic crises, which leads to decreased 
income, as well as policy changes such as prohibition of over the counter antibiotic sales and 
interventions such as awareness campaigns that can decrease antibiotic consumption as was 
the case for Chile in 1999 (Wirtz, et al., 2010). Utilization data such as large changes in 
consumption could also be used to inform further research with the aim of finding out the 
causes of the change and use that information to strengthen interventions (Wirtz, et al., 2010). 
 
The study by Klein, et al., (2018) used the same ATC/DDD classification system that was used 
for the above-mentioned study making the results comparable. Klein, et al., (2018) noted an 
increase of 4%, from 26.8 DID in 2000 to 25.7 DID in 2015, for high income countries (HIC) 
and an increase of 77%, from 7.6 DID in 2000 to 13.5 DID in 2015, for low and middle income 
countries (LMICs), leading to the conclusion that global increase of consumption was mostly 
attributable to high rates of consumption in LMICs. Although the rates for LMICs have 
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increased faster than that of the HICs the data shows that consumption in HICs is still higher 
than that in LMICs (Klein, et al., 2018). Klein, et al., (2018) results show that antibiotic 
consumption for UMICs increased by 78% from 12.0 DID in 2000 to 21.3 DID in 2015. 
 
2.2 Africa and the Southern African Development Community  
Literature on public sector consumption data in sub-Saharan African countries is rare as 
indicated in the recently published report on Surveillance of Antibiotic Consumption 2016-
2018 (World Health Organization, 2018). According to WHO (2018) based on 2015 sales data 
submitted by Burkina Faso, Cote d’Ivore and Burundi as well as 2016 import data provided by 
Tanzania. The report recorded a total antibiotic consumption of 27.3 DID for Tanzania, 
Burkina Faso 13.8 DID, Côte d’Ivoire 10.7 DID and Burundi with 4.4 DID. The report also 
stated that whilst data from other countries were national figures including both public and 
private sector Burundi only provided data from the public sector (World Health Organization, 
2018). When looking at consumption per pharmacological group penicillins were the highest 
consumed groups taking up 40% of the total consumption in Burkina Faso and Côte d’Ivoire, 
27% in Tanzania and 78% in Burundi. For  Burkina Faso and Côte d’Ivoire the penicillins were 
followed by   sulfonamides and trimethoprim which were 24% and 31%  in Burkina Faso and 
and  Côte d’Ivoire respectively. In Tanzania, the penicillins were followed by tetracyclines 
which took up 18% of the total consumption and quinolones 14%.  
 
The Resistance Map is a web based data collection tool supported by the Center for Disease 
Dynamics Economics and Policy which includes antibiotic consumption data from 75 countries 
from years 2000 to 2014 as obtained from IMSHealth's MIDAS and Xponent databases (The 
Center for Disease Dynamics Economics and Policy, 2017). The data on this website is 
reported in daily defined doses (DDDs) per 1,000 population, this unit was then divided by 365 
in order for it to become comparable to other data using DID unit. According to this source the 
antibiotic consumption for South Africa was reported to be on a steady increase from 16.08 
DID (2000), 17.35 DID (2004), 27.62 DID (2010), 24.89 DID (2011), 27.62 DID (2012), 29.67 
DID (2013), 23.92 DID (2014) to 25.14 DID in 2015 (The Center for Disease Dynamics 
Economics and Policy, 2017).  The South African private health sector also reported an 
increasing trend in the use of broad-spectrum antibiotics such as penicillins, fluoroquinolones, 
carbapenems and penems, carbacephems and glycopeptides with annual increases evident from 
2008 to 2011 (Essack, et al., 2011). This increase is similar to global trends. A study looking 
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at antimicrobial prescribing and cost in a South African private sector patient population noted 
that penicillins accounted for 26.43% of all antimicrobial products prescribed (Truter, 2015). 
Both of these studies looked at antibiotic consumption in humans. 
 
2.3 Namibia 
The total population for Namibia was projected at 2,143,411 million in 2010 and 2,399,057.00 
in 2016 ( Central Bureau of Statistics, 2006). Its variations per region and over time are 
indicated in below Table 1 and Figure 1 extracted from Central Bureau of Statistics data (2006). 
 
Table 1: Population by region, Namibia, 2010-2016 
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2010          
113,573  
         
71,995  
         
73,135  
         
265,373  
         
336,617  
         
76,598  
              
265,992  
           
79,959  
         
245,788  
         
178,665  
         
184,175  
                 
163,457  
         
88,084  
         
2,143,411  
2011          
114,342  
         
72,483  
         
73,630  
         
273,659  
         
348,171  
         
77,581  
              
270,755  
           
81,473  
         
247,948  
         
180,777  
         
187,098  
                 
167,051  
         
89,125  
         
2,184,092  
2012          
115,114  
         
72,972  
         
74,127  
         
282,199  
         
360,116  
         
78,574  
              
275,598  
           
83,013  
         
250,122  
         
182,910  
         
190,065  
                 
170,721  
         
90,176  
         
2,225,707  
2013          
115,882  
         
73,459  
         
74,622  
         
290,984  
         
372,441  
         
79,574  
              
280,507  
           
84,576  
         
252,295  
         
185,054  
         
193,063  
                 
174,458  
         
91,233  
         
2,268,150  
2014          
116,640  
         
73,940  
         
75,110  
         
300,000  
         
385,135  
         
80,577  
              
285,463  
           
86,157  
         
254,453  
         
187,197  
         
196,082  
                 
178,252  
         
92,290  
         
2,311,294  
2015          
117,378  
         
74,407  
         
75,585  
         
309,232  
         
398,179  
         
81,576  
              
290,447  
           
87,748  
         
256,576  
         
189,326  
         
199,107  
                 
182,091  
         
93,339  
         
2,354,992  
2016          
118,087  
         
74,857  
         
76,042  
         
318,657  
         
411,548  
         
82,564  
              
295,434  
           
89,344  
         
258,643  
         
191,425  
         
202,121  
                 
185,960  
         
94,374  
         
2,399,057  
Source: Central Bureau of Statistics, 2006 
 
As can be seen in Table 1 and Figure 1 Kavango (265,373-2010; 318,657 -2016) and Khomas 
(336,617-2010; 411,548-2016) regions had the highest population from 2010 to 2016. Hardap 
(71,995-2010; 74,857 -2016) and Karas (76,042 -2010; 73,135-2016) regions have had the 
lowest populations from 2010 to 2016.  
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Figure 1: Population by region, Namibia, 2010-2016 
 
In the Namibian public health sector antibiotic use is monitored through an indicator-based 
system that uses data from the Pharmacy Management Information System (PMIS) which is a 
data collection system that belongs to the Ministry of Health and Social Services and is adopted 
from the World Health Organization (WHO). This tool monitors the number of prescriptions 
with antibiotics in the public health sector but is silent on the actual quantity of antibiotics 
being consumed (MoHSS, 2012). According to this tool the percentage of outpatient 
prescriptions containing antibiotics in the Namibian public health sector is well above the 
WHO acceptable range of 35% (MoHSS, 2012), with figures as high as 55% in 2012 and 49% 
in 2016 (MoHSS, 2016). The data from these indicators shows that much needs to be done in 
terms of reducing anti-microbial use in the country (Kibuule, et al., 2017). 
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Source: (MoHSS, 2016:22) 
Figure 2: Percentage of outpatient department prescriptions with an antibiotic, Namibia 
 
The Medicines and Related Substances Control Act of 2003 which regulates medicines 
distribution in Namibia prohibits the sale of antibiotics without prescription (MoHSS Namibia, 
2015). However, there is as yet no system in place to enforce prescription only antibiotic sales 
since the Namibian Medicines Regulatory Council does not compare dispensing records to 
prescriptions at the dispensing site. What is in place is that the dispensing records must be 
retained for at least five years, meaning that if the medicines regulatory body were to inspect, 
the records would be available to carry out the requisite cross checking between the antibiotics 
dispensed and the prescriptions presented for those antibiotics in retrospect (MoHSS Namibia, 
2015). 
 
Although Namibia has STGs and a NEMList, in place since 2011 and 2002 respectively, aimed 
at ensuring access to and rational use of medicines, these documents lack “concurrence” in 
terms of antibiotics. Kibuule, et al., (2017) suggests that this lack of “concurrence” between 
the treatment guidelines and the essential medicines list may lead to inappropriate use for the 
items on essential list and not in the guidelines, and possible lack of access for those in the 
guidelines and not in the list since the list is what determines what is to be procured by the 
central medical stores (CMS). 
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A study by Pereko et, al. (2016) looked at antibiotic consumption in the private sector of 
Namibia and analysed wholesale and prescription data from 2008 to 2011. The results of this 
study showed a 57% increase in unit sales of antibiotics over the four years using wholesale 
data (Pereko , et al., 2016). Pereko et, al. (2016) further showed increases in antibiotic 
consumption from 19.0 to 22.11, 29.05, and 35.41 DID in each of the years 2008 to 2011, 
respectively. This makes the overall average antibiotic consumption over the total study period 
in the Namibian private sector to 26.4 DID. According to the European Surveillance of 
Antimicrobial Consumption (ESAC) classification 2010, consumption figures of >22.38 DIDs 
are considered high consumers. The Pereko study also found a worrying increase in the use of 
broad spectrum vs. narrow spectrum antibiotics (Pereko , et al., 2016).. Additionally the study 
showed penicillins to be the most used antibiotic class, accounting for 39% of all antibiotic use 
for wholesale data (Pereko et, al 2016).  Data for antibiotic consumption in the public human 
health sector has not yet been analysed in DIDs. 
 
This finding is consistent with the findings in the study conducted in South Africa (Essack, et 
al., 2011). In the Namibia private sector penicillins were followed by cephalosporins, 
macrolides, tetracyclines, and quinolones in terms of frequency of use (Pereko et, al 2016). 
These usage patterns indicated a shift in preference from narrow-spectrum in favour of broad-
spectrum antibiotics; this is of concern since broad spectrum antibiotic use accelerates 
resistance through cross resistance (Pereko et, al 2016).  
 
According to Centre for Disease Dynamics, Economics & Policy (2015) a decrease in 
consumption of antibiotics could translate in to a decrease in resistance and even a return of 
potency of some antibiotics to previously resistant strains. This is evidenced by some high-
income countries with good stewardship programmes that have led to not only a decline in 
resistance patterns but also a decrease in the actual quantities consumed (Centre for Disease 
Dynamics, Economics & Policy, 2015).  
 
2.4 Namibia’s National Antimicrobial Resistance Action Plan (NAAP)  
The Global Action Plan (GAP) to tackle AMR was endorsed at the 68th World Health 
Assembly in May 2015 (WHO, 2015). All WHO member states including Namibia agreed to 
prepare a National AMR Action Plan (NAAP) in line with the GAP. The NAAP was preceded 
by a situation analysis that was conducted from February 2017 to March 2017 through a highly 
http://etd.uwc.ac.za/
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consultative process. Key stakeholders from the Ministry of Agriculture, Water and Forestry, 
Ministry of Health and Social Services, Ministry of Environment and Tourism, Training 
Institutions, private healthcare facilities and development partners, actively participated in the 
development process (MoHSS Namibia, 2017).  
 
The NAAP which was based on the findings from the situation analysis had the following key 
objectives (Namibia MoHSS, 2017): 
1. Surveillance – to achieve monitoring capacity through surveillance to capture essential 
information on AMR and inform decision making 
2. Prevention – to reduce the incidence of infection through effective hygiene and 
Infection Prevention and Control (IPC) measures 
3. Antimicrobial use – to optimize the use of antimicrobial medicines in human and animal 
health 
4. Awareness, Collaboration and Communication  - to improve awareness, collaboration 
and communication regarding AMR 
5. Education and Training - to improve understanding of AMR through education and 
training  
6. Research and Development – to promote research and development in prevention, 
medicine use, indigenous knowledge systems and medicinal plants 
As can be seen in the NAAP Namibia has adopted the “one health” approach to tackling AMR 
by ensuring that all key stakeholders have objectives addressed to them to tackle AMR across 
all sectors (Namibia MoHSS, 2017). This document will therefore serve as a guide for 
Namibia’s anti-microbial stewardship program. 
 
2.5 Consumption of antibiotics measured using WHO ATC classification system and the 
defined daily dose system  
The World Health Organization Anatomic Therapeutic Classification and Daily Defined Dose 
(WHO ATC/DDD) system is used to analyse and present medicine use information for the 
purpose of improving use (WHO, 2018). The ATC/DDD system standardizes the unit of 
measurement and therefore makes medicine use data comparable within and across countries 
as well as between different health care settings and over time. Within countries the 
standardised unit makes it possible to compare medicine use over different periods of time and 
allows for trend analysis (WHO, 2018). 
http://etd.uwc.ac.za/
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According to WHO (2018) medicine use data based on ATC and DDDs can be used to provide 
medicine consumption profiles nationally, regionally or for individual health facilities. Data 
can also be used by health systems to identify medicine use patterns and develop interventions 
to correct incorrect medicine use practices.  
 
The ATC/DDD system can use data from many sources e.g. sales data, dispensing data, patient 
encounter based data, patient survey data- which is collected at patient level as well as health 
facility data (WHO, 2018). The data is reported in units that take into account differences in 
population size such as DDDs per 1000 inhabitants per day, DDD per inhabitant per year, or 
as DDDs per 100 bed days (WHO, 2018). This provision allows for comparisons across various 
time periods and population groups and is good for identifying trends in consumption. 
 
The denominator used during the analysis of medicine use data must be chosen carefully and 
should depend on the selected health context. WHO (2018) recommends the following 
denominators: 
1. DDD per 1000 inhabitants per day (DID) gives us information about the proportion of 
the selected population using a particular medicine per day. In an example provided by 
WHO (2018): The figure 10 DDDs per 1000 inhabitants means that an average of 10 
DDDs of medicine are utilized on any given day of the time period under review out of 
a population of 1000 individuals. Thus 10/1000 (1%) of the population are receiving 
this drug each day in that year. This denominator is useful when comparing data 
between regions in a country or between countries. 
 
2. The DDD per 100 bed days is an ideal denominator for studying hospital consumption. 
A bed day in this case is defined by WHO (2018) as a day when the patient is confined 
to a bed and stays overnight in that hospital. When using this denominator it is 
important to ensure that the same definition for bed days is used for any study that you 
use for comparison purposes. In an example provided by WHO (2018): The figure 70 
DDDs per 100 bed days means that 70% of the inpatients receive one DDD of the 
medicine under review every day.   
 
3. DDD/patient: when the denominator is the patient then treatment intensity is measured 
(WHO, 2018). 
http://etd.uwc.ac.za/
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4. DDDs per inhabitant per year: According to WHO (2018) this indicator is ideal for 
medicines that are used for short durations such as antibiotics. It provides information 
about how long each inhabitant was treated per year. In an example provided by WHO 
(2018) 5 DDDs/inhabitant/year indicates that on average each inhabitant consumed 5 
days of medicine during the year under review.   
 
For the purpose of this study DID as an indicator was used so as to be comparable with 
previously conducted studies (Pereko, et al., 2016;Wirtz, et al., 2010). It is important to note 
that the DDDs only provide for a rough estimate of consumption this is due in part to the fact 
that the actual dose prescribed is not always equal to the DDD as the actual doses can differ 
depending on the indication, the age of the patient and the severity of the infection (WHO, 
2018).  
 
The anatomic therapeutic class (ATC) classification system uses active pharmaceutical 
ingredients to classify medicines into a system consisting of five different levels. The first level 
classifies medicines according to the part of the human system that they work on e.g. group J 
which consists of anti-infectives. From level two (2) to level four (4) medicines are further 
broken down into levels based on chemical, pharmacological or therapeutic sub-groups and the 
fifth (5th) and final level has the codes for the actual chemical substance (WHO, 2018). This 
concept is tabulated below in an excerpt from Mohulatsi (2016:21). In the below table 
amoxicillin is used as an example from the anatomical group of anti-infectives for systemic 
use.  
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Table 2: An example of ATC classification  
Level  Definition  Example  
1 Main anatomical group  J- Anti-infectives for systemic use  
2 Pharmacological /therapeutic 
subgroup  
J01- Antibacterials for systemic use  
3 Pharmacological subgroup  J01C- beta-lactam anti-bacterials, penicillins 
4 Chemical sub group  J01CA penicillins with extended spectrum 
5 Chemical substance  J01CA04- amoxicillin 
Source: Mohulatsi, 2016:21  
 
ATC and DDDs are updated annually and therefore differences can occur between versions of 
the ATC index. It is therefore important to indicate which index version was used for data 
compared over time as well as when comparisons are made between different countries at 
different times (WHO, 2018).  
 
The use of the ATC/DDD classification system fast becoming the tool of choice when it comes 
to measuring consumption of antibiotics. This is great since it allows one to do comparisons in 
usage within and between countries when a standard unit is used for analysis. There seems to 
be an increase in antibiotic consumption worldwide with the pharmaceutical group consisting 
of penicillins being the biggest contributor to consumption. There is also an increase in 
preference for broad spectrum antibiotics over the narrow spectrum antibiotics.   
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CHAPTER 3: METHODOLOGY 
 
3.1. Aim and Objectives  
 
3.1.1 Aim 
To describe the pattern of antibiotic consumption in the Namibian public sector based on 
distribution of antibiotics from Central Medical Stores (CMS) to the 13 Regions between 2010 
and 2016. 
 
3.1.2. Objectives  
1. To describe antibiotic consumption by volume according to each WHO ATC class 
between 2010 and 2016. 
2. To describe the consumption of selected antibiotics by volume between 2010 and 2016.  
3. To describe antibiotic class consumption per region in the Namibian public health 
sector between 2010 and 2016.   
 
3.2 Study Design   
The study used consumption data from distribution records which was collated and analysed 
to describe trends and usage patterns in the public health sector of Namibia as a trend analysis 
over a period of seven years. This study utilized the medicine issues data from the central 
medical stores (CMS) as well as that from the Oshakati multi-regional medical stores, which 
constitute the public health sector wholesalers in Namibia. Antibiotic usage for the period 1 
January 2010 through to 31 December 2016 was investigated. 
 
All medicines and health commodities for the public sector are centrally received by the CMS 
in Windhoek and distributed either directly to hospitals or through Rundu regional store which 
caters to the Kavango region and the Oshakati regional medical store which caters to a number 
of regions as depicted in the CMS distribution network (Appendix 1). This single distribution 
system ensures optimal reliability, efficiency, and security to support the implementation of 
health programmes (MoHSS, 2016). This CMS Distribution Network covers all public health 
facilities in the country which include 36 district hospitals and more than 250 health centres 
and clinics; this translates to 100 percent coverage of the public health sector. The CMS fleet 
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delivers supplies to designated sites every six weeks, according to a delivery schedule (MoHSS, 
2016).  
 
3.3 Data Sources  
Distribution/issues data is data which is generated during distribution of medicines, including 
antibiotics, to the health facilities, is considered suitable data to use in medicines use reviews 
(Pereko, et al., 2016; WHO, 2003). The advantage of this data source is that it is readily 
available and easy to access. For this study, issues data from CMS as well as from Oshakati 
multi-regional store was used.  
 
The data from CMS and the Oshakati multi-regional store contained the following data 
elements: 
 Stock code – this code is unique to each product strength as well as pack size, this 
means that each pack size has a different code 
 Product description containing generic name  
 Total distributed units per year per facility in a region with the exception of those in the 
region covered by the Rundu Regional medical store  
 
Population information was sourced from Republic of Namibia Population Projections  
( Central Bureau of Statistics, 2006). Medium variant projection was used due to the fact that 
there was no reason to expect substantial variations. 
 
3.4 Data Extraction  
The population was the units of all antibiotics distributed in the public health sector in the 
period between 1 January 2010 and 31 December 2016 stratified by year. The NEMList 
currently contains 146 antimicrobial formulations as listed in the attached Appendix 3. Due to 
the high burden of tuberculosis and HIV/AIDS, in Namibia (MoHSS Namibia, 2013), it was 
proposed that these specific groups of antibiotics were not included in this assessment as they 
may distort the results (WHO, 2003). Consequently, all antibiotics distributed were included 
in the study. Additionally, only data related to antibiotics for systemic use and belonging to 
WHO anatomical therapeutic classification (ATC) J01 was collected and analysed (WHO 
Collaborating Centre for Drug Statistics Methodology, 2018). This means that antibiotics 
formulated as topicals or eye drops were also excluded. 
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Data was extracted using all six digits of the ATC code which allowed for analysis by antibiotic 
group and by individual antibiotics as per the WHO (2017) recommended method for 
determining DID. The WHO ATC classification and DDD list from WHO 2018 were used 
(WHO, 2018). Data from 2010 to 2016 was extracted from CMS and Oshakati multi-regional 
medical store records by the senior pharmacists at these facilities. The data was received in 
Microsoft Excel® 2010 format.  
 
The researcher compiled a list of the antibiotics that would be included in the study by listing 
all the medicines in the WHO J01 class that were distributed by CMS between January 2010 
and December 2016. This list consisted of 128 different stock items and these items were 
arranged according to their ATC classification up to level 4 - the description of the medicine, 
the strength, pack size, specific DDD, route of administration, as well as its unique stock code 
allocated by the CMS. This unique list of items is attached as Appendix 4. The researcher then 
provided this list to a statistician to use to extract the data needed from the distribution data 
from CMS and collate the number of packs issued per item and per region. The data required 
to complete the data collection tool (Appendix 5) was extracted and collated by the statistician 
using R (Version 3.2.3, The R Foundation for Statistical Computing) and RStudio 
(Version 1.1.423, Integrated Development for R, RStudio Inc.). The output of this was a region 
specific listing of the total volumes issued of each antibiotic per year. The statistician was also 
able to provide a listing of the total number of items issued by CMS during the period under 
review, including the proportions that were antibiotics, those used in the analysis and the 
fraction of items discarded due to missing data or incompatible values –as was the case for 
negative quantities shipped. This was the extent of the involvement of the statistician.  
 
The senior pharmacist at CMS indicated that these negative values represented credit notes but 
due to the fact that they only represented 0.29% of the total entries included in the study they 
were left out of the calculation as it was difficult to determine which year they stemmed from, 
as some were written up to two years after the date of incorrect issue.  
 
The study variable location and time was identified for analysis to see how geographic location 
as well as time affected or changed the results of the study through stratification.  
http://etd.uwc.ac.za/
18 
 
3.5 Data Analysis 
All of the data analysis was carried out by the researcher using Microsoft Excel®. The WHO 
recommended ATC/daily defined dose (DDD) methodology was used to evaluate the 
consumption (WHO Collaborating Centre for Drug Statistics Methodology, 2018). DID, a 
consumption indicator reported as defined daily dose (DDD) per 1 000 population per day, was 
used to compare antibiotic use across settings and is a standard measure recommended by 
WHO (2017) which allows comparisons between countries, regions and over time. Data was 
presented using stacked bar charts and trend lines which demonstrated the variation in 
consumption by ATC classes in each region and over time as was done by Wirtz, et al. (2010). 
 
Each antibiotic was assigned a DDD obtained from the WHO Collaborating Centre for Drug 
Statistics Methodology (WHO, 2018). The DDD is calculated as unit strength × pack size × 
quantity sold/ DDD assigned. The data source used was kilograms of issues per year aggregated 
by region which were then converted to DDD per 1000 inhabitants per day (DID) as the unit 
of analysis. The issues data was then expressed as DDD/1,000 population/day using the 
following formula:  
 
DDD/1,000/day = (Total consumption in DDDs/Total population covered × 365) × 1,000.  
The population used for the issues data was 85% of the Namibian population per region, which 
is the population estimated to be serviced by the CMS (MoHSS, 2014). The number of days 
used was 365 days. Results were presented in DDD/1000/day of antibiotics consumed which 
identified the WHO ATC classes with the highest consumption nationally as well as per region 
and within the ATC class the specific antibiotic with the highest consumption trend was 
identified.  
 
3.6 Validity and Reliability  
To address validity of this study the WHO guidelines from the Collaborating Centre for Drug 
Statistics Methodology (2018) was followed throughout the process (WHO Collaborating 
Centre for Drug Statistics Methodology, 2018). In order to improve reliability all the data on 
the selected antibiotics was used and data over a large period (7 years) was extracted by the 
researcher. This minimized the risk to validity since the larger the sample, the more likely it is 
to be representative of the evaluation population (Chopra & Coveney, 2003) and in this case 
the “sample” is the whole population. The senior pharmacist at CMS was asked to review the 
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extracted data to ensure consistency and all queries that arose during data cleaning were 
discussed with the senior pharmacist at both CMS and the Oshakati Multi-regional store.  
 
3.7 Limitations 
DDD is an average unit measure and does not account for actual doses used per individual 
patients and is also based on average adult dose and not that of a child which means that the 
DID might have been higher or lower depending on the age distribution of the population 
consuming that antibiotic (Wirtz, et al., 2010).  
 
In this study secondary data was used which were the issues data from the country’s CMS to 
the public health service facilities. This data was originally recorded for administrative and 
billing purposes only. From this source, data can be broken down into two components namely 
cost and volume of antibiotics consumed per given time period per geographical or 
administrative area. The limitation with using issues data is that not all medicines issued to the 
facilities are consumed as losses occur from expiries, theft as well as breakage (Wirtz, et al., 
2010). However, these losses are likely to be consistent over time and as such changes in issued 
volumes are likely to reflect real changes in consumption trends. An additional threat to 
external validity is that some antibiotics were sourced directly by the health facilities during 
this period from a supplier other than CMS. This form of procurement, known as ‘buyouts’, is 
only utilised in very few exceptional cases and was therefore not included in this study since 
this data is not routinely collected nor readily available and is expected to be minimal (MoHSS, 
2016). Another possible limitation with retrospective data is that the data is designed for the 
purpose of billing and not necessarily for research purposes so there is a chance for inaccuracy 
and perhaps some data losses. The positive benefit of this data source is that this data is subject 
to financial audit. 
 
From the total number of items issued by CMS during the period under review, a fraction of 
items were discarded due to missing data such as negative quantities shipped. The senior 
pharmacist at CMS indicated that these values represented credit notes but due to the fact that 
they only represented 0.29% of the total entries included in the study they were left out of the 
calculation as it was difficult to determine which year they stemmed from, as some were written 
up to two years after the data of incorrect issue. 
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3.8. Ethical statement   
Ethical clearance for this study was obtained from the University of the Western Cape 
Biomedical Research Ethics Committee. Permission for access and use of the data for the study 
was provided by MoHSS. These letters are attached as Appendix 6. As the study involved the 
use of retrospective data on medicines issues from the CMS, there were direct interactions with 
patients or health services staff and no risk of direct harm to patients or staff. All the data 
received from CMS was kept safe and was only accessed by the researcher and the bio 
statistical consultant. All hard copies of data were stored in a locked cabinet with only the 
researcher having access. Both electronic data and hard copies will be stored for a period of 
five years. 
 
The results of this study will be shared with all health professionals at management level in 
MoHSS and then cascaded down through the official communication channels in order for it 
to reach all health care workers in the health sector including those involved in anti-microbial 
stewardship programme.  
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CHAPTER 4: RESULTS  
 
4.1 Introduction  
This chapter describes the findings of the study, which described the pattern of antibiotic 
consumption in the Namibian public sector between 2010 and 2016 based on distribution of 
antibiotics from Central Medical Stores (CMS) to the 13 Regions between 2010 and 2016.  
A total of 227,068 items were issued from the CMS and multi-regional medical stores 
(MRMS), to the public health facilities in Namibia, during the period under review. Of those 
items 41,025 (18%) were antibiotics as defined by anatomical therapeutic classification (ATC) 
class J01 of the WHO classification (WHO, 2018). Of those 41,025 a total of 120 (0.29%) 
items were found to have negative issued quantities. According to the senior pharmacist at 
CMS these were credits issued to the facilities and cannot be allocated to a particular year as 
these credits could overlap in years. The researcher then decided to exclude these 120 (0.29%) 
entries from the study thus 40,905 items were included in the analysis.  
 
The results are presented as follows for the years 2010 to 2016: 
4.2 National trend of antibiotic consumption by total volume 
4.3 National trend of antibiotic consumption by total volume per antibiotic class  
4.4 National consumption trends for selected antibiotics by volume 
4.5 Regional trends of antibiotic consumption by total volume  
4.6 Regional consumption by antibiotic class 
 
Since the public health sector was estimated to serve 85% of the population (MoHSS, 2014), 
the national and regional DIDs were determined using 85% of the national and regional 
population figures respectively.   
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4.2 National trend of antibiotic consumption by total volume 
The national antibiotic consumption for the Namibian public sector for the period between 
2010 and 2016 is presented in Figure 3. During the period under review the DDD per 1000 
inhabitants per day (DID) for the public sector had a steep rise from 38.31 DID in 2010 to 
41.48 DID in 2011 from where it dipped slightly to 39.36 DID (2012). From there it rose to 
42.70 DID (2013) and 43.31 DID (2014) to a peak of 43.86 DID in 2015 and thereafter there 
was a slight decrease to 43.37 DID in 2016.  
 
 
Figure 3: National Antibiotic consumption trend, Namibia, 2010-2016  
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4.3 National trend of antibiotic consumption per antibiotic class 
The consumption per antibiotic class consumed in Namibia was analyzed per year and is 
presented in Table 3.  
 
Table 3: Trends of national antibiotic consumption in Namibia by antibiotic class, 2010-
2016  
  Total DID's % of total 
consumption 
2010 
% of total 
consumption 
2016 
2010 2011 2012 2013 2014 2015 2016 
Aminoglycoside antibacterials 0.35 0.31 0.32 0.28 0.45 0.24 0.26 0,91% 0,61% 
Amphenicols  0.04 0.03 0.02 0.02 0.01 0.01 0.01 0,11% 0,02% 
Beta lactam antibiotics, 
penicillins 
12.39 13.39 10.94 13.13 12.76 12.95 14.17 
32,33% 32,66% 
Macrolides, lincosamides and 
streptogramins 
1.91 2.25 2.04 2.02 2.24 2.11 2.52 
4,99% 5,81% 
Other antibacterials 0.18 0.15 0.26 0.32 0.12 0.38 0.37 0,47% 0,86% 
Other beta lactam 
antibacterials 
0.78 1.02 1.02 1.13 1.28 1.39 1.10 
2,03% 2,54% 
Quinolone antibacterials 1.21 1.49 1.22 1.28 1.15 1.04 1.30 3,16% 3,00% 
Sulphonamides and 
trimethoprim 
19.40 21.00 22.04 23.22 23.17 24.30 21.99 
50,65% 50,69% 
Tetracyclines  2.05 1.83 1.79 1.32 2.14 1.44 1.65 5,36% 3,80% 
Total 38.31 41.48 39.65 42.70 43.31 43.86 43.37 100,00% 100,00% 
*other beta lactam antibacterials include cephalosporins and carbapenems 
*other antibacterials include vancomycin, nitrofurantoin, fusidic acid and linezolid  
 
In 2010 as presented in Table 3 and depicted in Figure 4, sulphonamides and trimethoprim 
(51%) had the highest percentage of the total consumption followed by beta-lactam penicillins 
(32%) and then tetracyclines (5%) macrolides, lincosamides and streptogramins (5%) with and 
amphenicols and other antibacterials (0%) having the lowest consumption figures. For 2016 
the highest consumed antibiotic class was still sulphonamides and trimethoprim (51%) 
followed by beta lactam penicillins (33%) and then macrolides, lincosamides and 
streptogramins (6%) as well as tetracyclines (4%). In 2016, amphenicols (0%) had the lowest 
consumption figures. 
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Figure 4: Proportion of total consumption per antibiotic class, Namibia, 2010 & 2016 
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year 2010 12.39 to 13.13 DID in 2013 where after it dropped to 12.76 DID in 2014 and further 
increased steadily to reach 14.17 DID in 2016.  
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
%
 o
f 
to
ta
l c
o
n
su
m
p
ti
o
n
Antibiotic class
% of total consumption 2010 % of total consumption 2016
http://etd.uwc.ac.za/
25 
 
The trend for the amphenicol class of antibiotics was the lowest consumed of all the classes. It 
started off at 0.04 DID in 2010 followed by a drop to 0.03 in 2011 where after it further 
decreased to 0.02 in 2012 and 2013 followed by a decrease to 0.01 DID from 2014 to 2016. 
The trend for the other beta lactam antibacterials indicated a low consumption of this class as 
well. The trend showed a DID of 0.78 in 2010 followed by an increase to 1.02 in 2011, there 
was a rise from 2012 (1.02 DID) to 2013 (1.13 DID) and 1.28 DID in 2014 from where it rose 
to 1.39 DID in 2015. It then dropped back down to 1.10 DID in 2016. 
 
 
 
Figure 5: National antibiotic consumption trends per antibiotic classification, Namibia, 
2010-2016 
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4.4 National consumption trends for selected antibiotics by volume between 2010 and 
2016 
The distribution of the two antibiotic classes with the highest consumption was further analyzed 
and the results are shown in Tables 4 & 5 and Figure 6 & 7. 
 
Table 4 and Figure 6 show that of all the antibiotics in the sulphonamide and trimethoprim 
class the co-trimoxazole 80+400mg tabs have the highest consumption in the Namibian public 
health sector. According to Table 4 co-trimoxazole 80+400mg tabs constituted 83% of the total 
sulphonamide and trimethoprim antibiotics consumed in 2010 and 86% in 2016. Co-
trimoxazole 40/200mg/5ml syrup was the second highest consumed formulation in the class 
with 11% (2010) and 14% (2016) of the consumption within the group being attributed to this 
formulation. 
 
Table 4: Consumption trends of sulphonamides and trimethoprim, Namibia, 2010-2016 
in DID 
  201
0 
201
1 
201
2 
201
3 
201
4 
201
5 
201
6 
% of 
total 
2010 
% of 
total 
2016 
Co-trimoxazole 
160+800mg tabs 
1.16
1 
0.21
4 
0 0 0 0 0 5,98% 0,00% 
Co-trimoxazole 
40/200mg/5ml 
2.16
2 
3.38
9 
2.89
1 
3.14
2 
3.40
6 
2.92 3.09 11,14% 14,05% 
Co-trimoxazole 
80+400mg tabs 
16.0
7 
17.4 19.1
4 
20.0
8 
19.7
6 
21.3
7 
18.8
9 
82,84% 85,93% 
Co-trimoxazole 
80mg/400mg inj 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0,04% 0,02% 
Total 19.4
0 
21.0
0 
22.0
4 
23.2
2 
23.1
7 
24.3
0 
21.9
9 
100,00
% 
100,00
% 
 
Figure 6 indicates that the consumption for co-trimoxazole 80 + 400 mg tabs was, in line with 
the national consumption patterns, rose from 16.07 DID (2010) to 17.4 DID (2011) and then  
to 19.14 DID (2012). From there it rose steadily to 20.08 DID (2013) and to its peak of 21.37 
DID in 2015. This rise was followed a slight decrease to 18.89 DID in 2016. 
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Figure 6: Consumption trends of sulphonamides and trimethoprim, Namibia, 2010-2016 
 
Table 5 and Figure 7 show that of all the antibiotics in the penicillins class, amoxicillin-based 
formulations have the highest consumption in the Namibian public health sector. According to 
Table 5, amoxicillin-based formulations constituted 70.75% of the total penicillin class 
antibiotics consumed in 2010 and 73.04% in 2016, this was followed by pen V K, which 
constituted 19.87% of the penicillins class consumption in 2010 and 16.27% in 2016. 
Cloxacillin constituted 7.01% in 2010 and 8.66% in 2016 of the total consumption within this 
class. 
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Table 5: Consumption trends of penicillins, Namibia, 2010 to 2016 in DID 
  2010 2011 2012 2013 2014 2015 2016 % of total 
2010 
% of 
total 
2016 
Amoxicillin 8.76 9.07 7.31 9.93 9.62 9.85 10.35 70.75% 73.04% 
Cloxacillin 0.87 1.09 1.22 0.99 1.00 1.18 1.23 7.01% 8.66% 
Benzathine penicillin 0.15 0.07 0.07 0.09 0.08 0.06 0.07 1.21% 0.46% 
Pen V K 2.46 3.00 2.11 1.92 1.89 1.74 2.30 19.87% 16.27% 
Ampicillin 0.13 0.12 0.18 0.18 0.16 0.11 0.21 1.03% 1.46% 
Piperacillin/tazobactam 
& Procaine 
0.02 0.05 0.05 0.03 0.02 0.02 0.02 0.13% 0.12% 
Total 12.39 13.39 10.94 13.13 12.76 12.95 14.17 100.00% 100.00% 
 
 
In line with the national consumption trends, the DID for amoxicillin rose from 8.76 DID 
(2010) to 9.07 DID (2011) from where it dipped slightly to 7.31 DID (2012). Thereafter, it rose 
steadily to 9.93 DID (2013) and to 9.85 DID in 2015. This rise continued to a high of 10.35 
DID in 2016. 
 
 
 
Figure 7: Consumption trends of Penicillins, Namibia, 2010 to 2016 
 
  
0,00
2,00
4,00
6,00
8,00
10,00
12,00
2010 2011 2012 2013 2014 2015 2016
D
ID
Year
Amoxycillin Cloxacillin
Benzathine Pen V K
Ampicillin Piperacillin/tazobactam & Procaine
http://etd.uwc.ac.za/
29 
 
4.5 Trends of antibiotic consumption per region in Namibia 
Table 6 shows the antibiotic consumptions rates varied by region and over time and ranged 
from a low of 22.32 DID in Omaheke region in 2010 and a high of 84.79 DID in the Zambezi 
region in 2016. In 2010 Zambezi (10%), Erongo (10%) and Kavango (10%) regions were 
responsible for a combined total of 30% of the total antibiotic consumption; whilst in 2016, 
Hardap (9%), Karas (9%), Kavango (9%) and Zambezi (14%) contributed 41%.  The regions 
Ohangwena (4%, 2010 and 6%, 2016), Omaheke (4%, 2010 and 5%, 2016), and Otjozondjupa 
(6%, 2010 and 6%, 2016) had the lowest consumption figures in the country.  
 
Table 6: Trends of antibiotic consumption by region in Namibia, 2010-2016 in DID 
  2010 2011 2012 2013 2014 2015 2016 Min Max 
% of total 
consumption 
2010 
% of total 
consumption 
2016 
Erongo 49.68 58.75 55.69 57.25 58.47 60.41 44.91 44.91 60.41 9,80% 7,52% 
Hardap 39.83 38.73 44.47 52.33 47.77 49.83 54.69 38.73 54.69 7,86% 9,15% 
Karas 43.24 37.42 42.63 50.89 45.79 58.91 51.33 37.42 58.91 8,53% 8,59% 
Kavango 50.98 43.10 43.47 46.03 47.01 43.24 52.03 43.10 52.03 10,06% 8,71% 
Khomas 36.07 44.70 44.03 37.68 41.05 35.04 36.18 35.04 44.70 7,12% 6,05% 
Kunene 41.67 47.10 43.47 36.64 46.51 50.37 43.49 36.64 50.37 8,22% 7,28% 
Ohangwena 22.48 29.84 29.10 38.91 31.46 32.07 35.19 22.48 38.91 4,43% 5,89% 
Omaheke 22.32 31.72 24.50 33.45 34.85 29.54 32.81 22.32 34.85 4,40% 5,49% 
Omusati 40.54 38.78 35.21 39.64 44.07 48.19 47.02 35.21 48.19 8,00% 7,87% 
Oshana 34.69 39.96 37.48 38.07 33.22 41.73 35.36 33.22 41.73 6,84% 5,92% 
Oshikoto 45.99 42.55 38.09 50.59 48.16 49.52 43.35 38.09 50.59 9,07% 7,26% 
Otjozondjupa 30.36 39.56 34.28 35.34 39.18 43.59 36.41 30.36 43.59 5,99% 6,09% 
Zambezi 49.05 59.87 57.47 61.57 74.92 72.21 84.79 49.05 84.79 9,68% 14,19% 
National 38.31 41.48 39.65 42.70 43.31 43.86 43.37 38.31 43.86     
 
Figure 8 depicts the trend of consumption by region. The trend indicates that Karas, Kavango, 
Oshikoto, Hardap, Erongo and Zambezi regions have consumption trends that are higher than 
the national DID. The highest consumption was recorded for the Zambezi region and the trend 
line showed a steep rise from a low of 49.05 DID (2010) to 59.87 DID (2011) where after it 
decreased to 57.47 DID (2012) and then rose again to 61.57 DID (2013) and  74.92 DID (2014). 
It fell slightly to 72.21 DID in 2015 and the reached a peak of 84.79 DID in 2016. Kavango 
region had a DID of 50.98 in 2010 which dropped to 43.10 DID in 2011 and 43.47 DID in 
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2012. From there the trend continued its rise to 46.03 DID in 2013 and 47.01 in 2014 and this 
was followed by a drop to 43.24 DID in 2015 and a peak of 52.03 DID in 2016.  
 
According to Figure 8, Omaheke region had the lowest consumption of antibiotics in the 
country. The trend started off at 22.32 DID in 2010 followed by a steep rise to 31.72 DID in 
2011 where after it decreased drastically to 24.50 DID in 2012 and rose to 33.45 DID in 2013. 
In 2014 the trend increased slightly to 34.85 DID and went back down to 29.54 DID in 2015 
and then continued steadily upwards to reach 32.81 DID in 2016. Figure 8 indicates that the 
Ohangwena region had the second lowest consumption of antibiotics in the country following 
Ohangwena. The trend started off at 22.48 DID in 2010, followed by an increase to 29.84 DID 
in 2011 where after it dipped to 29.10 in 2012. In 2013 it rose to 38.91 DID and dropped again 
to 31.46 DID in 2014. In 2015 the trend increased slightly to 32.07 DID and 35.19 DID in 
2016. 
 
 
Figure 8: Trends of antibiotic consumption by region in Namibia, 2010-2016 
 
Table 7 shows that in terms of relative change, with 2010 as a baseline, consumption of 
antibiotics increased in all the regions, except for Erongo and Oshikoto where there a decrease 
was observed. The largest percentage increase was in Zambezi region, with an increase of 
72.85%, followed by Ohangwena with an increase of 56.53%. 
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Table 7: Changes in antibiotic consumption by region in Namibia, 2010-2016 
  
Antibiotic 
consumpti
on, 2010 
(DID) 
Antibiotic 
consumpti
on, 2016 
(DID) 
Change in 
consumpti
on 2010-
2016 
(DID) 
Percen
t 
change 
within 
region
s 
Minimum 
annual 
consumpti
on 2010-
2016 
(DID) 
Maximum 
annual 
consumpti
on 2010-
2016 
(DID) 
Erongo  49.68 44.91 -4.77 -9.60 44.91 60.41 
Hardap 39.83 54.69 14.85 +37.29 38.73 54.69 
Karas 43.24 51.33 8.08 +18.69 37.42 58.91 
Kavango 50.98 52.03 1.06 +2.08 43.10 52.03 
Khomas 36.07 36.18 0.11 +0.30 35.04 44.70 
Kunene 41.67 43.49 1.82 +4.37 36.64 50.37 
Ohangwena 22.48 35.19 12.71 +56.53 22.48 38.91 
Omaheke 22.32 32.81 10.49 +46.99 22.32 34.85 
Omusati 40.54 47.02 6.48 +15.99 35.21 48.19 
Oshana 34.69 35.36 0.67 +1.92 33.22 41.73 
Oshikoto 45.99 43.35 -2.63 -5.72 38.09 50.59 
Otjozondju
pa 30.36 36.41 6.05 +19.93 30.36 43.59 
Zambezi 49.05 84.79 35.74 +72.85 49.05 84.79 
Regional 
average 
38.31 43.37 5.06 
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4.6 Regional consumption by antibiotic class 2010 and 2016 
Looking at the antibiotic consumption by region and by antibiotic class Figure 9 & 10 indicates 
sulphonamides and trimethoprim as the highest consumed class across all the regions for both 
2010 and 2016. This examination was conducted for the years 2011 to 2015 and is available in 
Appendix 7. 
 
 
 
Figure 9: Antibiotic consumption by region by antibiotic class, Namibia, 2010  
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Figure 10: Antibiotic consumption by region by antibiotic class, Namibia, 2016 
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Table 8: Antibiotic consumption in the Zambezi region and national total, by antibiotic 
class, 2010 & 2016  
ATC 3 class  Zambezi National 
2010 
DID 
% of total 
consumption 
2010 
2016 
DID 
% of total 
consumption 
2016 
2010 
DID 
% of total 
consumption 
2010 
2016 
DID 
% of total 
consumption 
2016 
Aminoglycoside 
antibacterials 
0.39 0,80% 0.43 0,50% 0.35 
0,91% 
0.26 
0,61% 
Amphenicols  0.04 0,07% 0.01 0,01% 0.04 0,11% 0.01 0,02% 
Beta lactam 
antibiotics, penicillins 
18.15 37,00% 26.60 31,37% 12.39 
32,33% 
14.17 
32,66% 
Macrolides, 
lincosamides and 
streptogramins 
5.54 11,29% 5.28 6,23% 1.91 
4,99% 
2.52 
5,81% 
Other antibacterials 0.00 0,00% 0.45 0,53% 0.18 0,47% 0.37 0,86% 
Other beta lactam 
antibacterials 
0.33 0,67% 1.63 1,92% 0.78 
2,03% 
1.10 
2,54% 
Quinolone 
antibacterials 
1.10 2,23% 1.87 2,21% 1.21 
3,16% 
1.30 
3,00% 
Sulphonamides and 
trimethoprim 
20.94 42,69% 45.06 53,14% 19.40 
50,65% 
21.99 
50,69% 
Tetracyclines  2.57 5,24% 3.46 4,08% 2.05 5,36% 1.65 3,80% 
Total 49.05 100% 84.79 100% 38.31 100,00% 43.37 100% 
 
 
Antibiotic consumption per antibiotic class per region are shown in Table 8 and Figures 9 and 
10.  The classes with the highest consumption in Zambezi for both 2010 and 2016 were 
sulphonamides and trimethoprim (43%, 2010 and 53%, 2016) followed by penicillins (37%, 
2010 and 31%, 2016), which were in line with the national picture.  
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Figure 11: Regional antibiotic consumption trends per antibiotic classification, Zambezi, 
2010-2016 
 
The trend line for the consumption of the antibiotics consumed in Zambezi is presented in 
Figure 11 and depicts a steady increase in consumption of sulphonamide and trimethoprim 
from 2010 to 2016. The consumption of penicillins show an initial rise from 2010 to 2011 
followed by a decline up to 2013 where after it increases steadily up to its peak in 2015 and 
slight decrease to its 2016 value. The consumption of macrolides, lincosamides and 
streptogramin class showed a steady near linear progression from 2010 to 2016. Trend lines 
for the other regions are available in Appendix 8. 
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Figure 12: Antibiotic consumption trend, Zambezi vs national average, and 2010-2016  
 
Figure 12 shows a comparison of the trend line for consumption of antibiotics in Zambezi with 
that of the national average between 2010 and 2016. It was clear that consumption in Zambezi 
was much higher than the national DID, and that the Zambezi region showed a steady rise 
during the period whilst national trend line maintained a near linear progression. 
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CHAPTER 5: DISCUSSION  
 
5.1 Introduction 
As antibiotic resistance is driven by the volume of consumption, understanding how 
consumption works over time and between countries or regions could serve as a baseline 
measurement for AMR stewardship initiatives. This study assessed the pattern of antibiotic 
consumption in the Namibian public sector between 2010 and 2016 based on distribution of 
antibiotics from Central Medical Stores (CMS) to each of the 13 Regions between 2010 and 
2016. The WHO recommended ATC/daily defined dose (DDD) methodology was used to 
evaluate the consumption (WHO, 2018). The study analyzed a total of 24,110 antibiotic 
distributions issued from the Central Medical Store (CMS), with antibiotics as defined by 
anatomical therapeutic classification (ATC) class J01 of the WHO classification (WHO, 2018).  
 
The discussion is presented as follows: 
 National trend of antibiotic consumption by total volume versus international trends 
 National trend of antibiotic consumption by total volume per antibiotic class  
 National consumption trends for selected antibiotics by volume 
 Regional trends of antibiotic consumption by total volume 
 Regional consumption by antibiotic class 
 
5.2 National trend of antibiotic consumption by total volume versus international trends 
Namibia’s antibiotic consumption for the public sector increased by 13.2% from 38.31 DID in 
2010 to 43.37 DID in 2016, with an average of 41.81 DID during the study period. Namibia is 
classified by the World Bank as an upper middle income country (UMIC) (World Bank Group, 
2018). Although the increase in antibiotic consumption in Namibia was lower in percentage 
terms when compared to other UMICs as well as South Africa in Klein, et al., (2018), the 
absolute numbers are still twice as high as other UMICs in 2016. The DID for Namibia is 
comparable to countries such as Turkey, Tunisia, Greece and Spain which had similar DIDs in 
2015 (Klein, et al., 2018). South Africa’s consumption increased by 56% from 16.08 DID in 
2000 to 25.14 DID in 2015 (Klein, et al., 2018).  
 
The differences could be partially attributed to the methodology of the studies as the study 
conducted by Klein, et al., (2018) used the 2016 WHO ATC/DDD classification, whilst Pereko, 
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et al., (2015) used the  2013 version and this study used the 2018 version. As DDD are revised 
and added to over the years this could provide for some slight differences in the results. 
However, the trend and percentage change should still be comparable. The Klein, et al., (2018) 
study also indicated that molecules not included in the ATC/DDD 2016 classification were 
provided for through estimates from other sources whilst this study only used those that were 
already allocated DDDs by the ATC/DDD system. This could mean that more molecules were 
included in the Klein, et al., (2018) study than for the other studies which could increase the 
DID reported. For this public sector study all the required data was available and was used so 
no sampling was done. However, the data for the Klein, et al., (2018) study used sampling and 
extrapolated where no data was available which would make the Namibia public sector study 
more accurate since no sampling was done.  
 
The Pereko, et al., (2015) study only had wholesale data from one of the two main wholesalers 
in the private sector for Namibia, meaning that not all the data was available. The Pereko, et 
al., (2015) study only covered the private sector and this study the public sector whilst the Klein 
et al., (2018) study looked at whole countries for the most part. However Klein et al., (2018) 
does depend on IQVIA® data which in some cases only collects private sector data and does 
not collect public sector data. In some countries like South Africa they do collect both but not 
all. So their figures may also be an underestimate where products are procured by both the 
public and private sectors. It is therefore possible that the figures from this study could have 
been lower had they been a combination of both private (lower) and public (higher) sector 
consumption instead of sector specific. This also means that the Namibia data from each study 
cannot be generalized to the whole population since neither of the studies covered both sectors. 
Other than that, all the methodologies were the same as the reccomended WHO ATC/DDD 
methodology.The sources for the population data also differed as for this study projections 
from the Central Bureau of Statistics, (2006) were used whilst Klein et al., (2018) used the 
World Bank data bank population data. 
 
According to the European Surveillance of Antimicrobial Consumption (ESAC) classification 
(Mohulatsi, 2016), Namibia is a high antibiotic consumer based on the fact that both the private 
and public sector consumption figures are well above 22.38 DIDs. Namibia’s public sector 
consumption rate is higher than that of the Namibian private sector which showed an increase 
of 25% from 19 DID in 2008 to 35.41 DID in 2011 (Mohulatsi, 2016). It is also higher than 
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that of even the high income countries’ consumption as reported by Klein, et al., (2018) and 
Wirtz, et al.,(2010). The difference between private and public sector consumption in Namibia 
could be attributed to many factors one of them being that the public sector medicines are 
provided at a very low cost about USD 0.50 inclusive of consultation and screening. As of 2017 
only about 200,000 out of a total of 2, 5 million Namibians are covered by medical aid, 
translating to only 8% of Namibians having medical aid (NAMAF, 2017). In the private sector 
a patient is charged per item out of pocket and those that have medical aid still have to pay 5% 
to 30% per item co-payment when using insurance which is higher than the USD 0.50 paid in 
the public sector. This economic element might have played a role in reducing the consumption 
in the private sector.  
 
Klein, et al., (2018) proposed that high consumption is attributable to high income as well as 
high burdens of infectious diseases. This scenario is typical for an UMIC such as Namibia with 
high burden of infectious diseases, such as tuberculosis, HIV and malaria, prevailing poor 
socio-economic conditions, such as poor sanitation (MoHSS Namibia, 2013) which leads to 
increased exposure to disease causing agents. These diseases are then in turn treated with 
antibiotics and this leads to an increase in the use of antibiotics. Namibia’s gross domestic 
product (GDP) has been on the rise for most of the period under review (tradingeconomics, 
2018). According to Klein, et al., (2018) an increase in GDP provides for access to more goods 
and services including antibiotics leading to increase in access to antibiotics and therefore an 
increase in consumption. Rising GDP, as is the case for Namibia, is also associated with 
urbanization, which involves people from rural areas moving to more economically active 
urban areas in search for jobs (Klein, et al., 2018). Many of these people live in poor conditions 
as the urban areas that they move to are usually unable to provide sufficient services for the 
rapid influx of people that usually occurs. The poor living conditions in turn lead to further rise 
in infectious diseases and other illnesses that, although not infectious, may still lead to irrational 
use of antibiotics (Klein, et al., 2018). 
 
According to Pereko, et al., (2015) one of the strategies that can be used to improve rational 
use of antibiotics is the provision and use of treatment guidelines/antibiotic protocols. The 
Namibian standard treatment guidelines (STGs) were launched in 2011 (MoHSS, 2011). The 
launch was accompanied by training aimed at educating the prescribers (Akpabio, et al., 2014). 
Before Namibia had the STGs there were several guidelines in place but none as 
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comprehensive as the STGs (MoHSS, 2011). One would have expected that the launch of the 
guidelines would have some influence on prescribing practices and reflect on the consumption 
of antibiotics. However, Akpabio, et al., (2014) in a study carried out between 2012 and 2013 
found a low compliance level of about 27% to the STGs. This meant that the effect of the STG 
was not as pronounced as expected. 
 
The lack of concurence between the STGs and NEMList could also have negatively affected 
the prescribing practices. This  negative effect stems from lack of access for the items in the 
STGs and not in the NEMList , since the public sector procurement system relies mostly on 
the NEMList for procurement. Innapropriate use would be expected for the items in the 
NEMList and not in the guidelines due to  lack of guidance for their use.  
 
Although the STGs compliance rate does not allow one to make a direct correllation, it was 
noted that the total consumption of antibiotics did take a slight dip in 2012 which was be the 
first year in which the guidelines were used. This dip was from 41.48 DID in 2011 to 39.65 
DID in 2012. However, there is a need to further analyse the use of antibiotics in order to 
determine other causes of this high use and find ways to reduce it (Mohulatsi, 2016). This data 
shows how much antibiotic are being consumed and that the rate is higher than average. 
However, it does not say whether the use is warranted vis-à-vis the disease burden or socio-
economic conditions within which the population lives. To answer this question one would 
need to conduct another study. What the increasing DID tells us however is that the 
consumption is increasing faster than the population growth since the DID unit measures per 
inhabitant (Mohulatsi, 2016). 
 
5.3 National trend of antibiotic consumption by total volume per antibiotic class  
Within the antibiotic classes, the class with the highest consumption in the public sector was 
sulphonamide and trimethoprim which made up 51% of the total antibiotic consumption in 
2010 and again in 2016. The reason for the high consumption of the sulphonamide and 
trimethoprim class is due to the fact that co-trimoxazole was used as prophylaxis for 
opportunistic infections in HIV positive patients during the period under review. As at March 
2016 Namibia had about 220 000 HIV positive people of which there were 148 920 patients 
on antiretroviral treatment. (Namibia MoHSS, 2016; MOHSS, 2016). The antiretroviral 
treatment guidelines in Namibia recommends co-trimoxazole prophylaxis for all adults with 
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HIV with a CD4 cell count of ≤ 350 or in WHO Clinical Stage 3 or 4 disease (MOHSS, 
2016).The results of this study indicate that many of these patients are taking co-trimoxazole 
as a daily dose (MoHSS, 2011;MoHSS, 2017). Beta lactam penicillins were the second highest 
consumed antibiotic class. This is to be expected as they are the first line treatment in the 
majority of the cases needing antibiotics in Namibia (MoHSS, 2011). However, according to 
Klein, et al., (2018) the consumption of penicillins could be exaggerated due to the fact that 
the assigned DDD is much lower than the actual prescibed dose. Macrolides, lincosamide and 
streptogramin classes only contributed 6% to consumption. The private sector for Namibia had 
a similar affinity for the use of beta lactam antibiotics, penicillins, cephalosporins and 
macrolides, lincosamide and streptogramins as these are the highest consumed antibiotics in 
the private sector (Pereko , et al., 2016). However, sulphonamides did not appear in their top 9 
highest consumed antibiotics (Mohulatsi, 2016). This would suggest that patients being treated 
for HIV either receive their prophylaxis in the public sector or the private sector does not make 
use of co-trimoxazole as prophylaxis. 
 
Klein, et al., (2018) further reported a global increase in consumption of last resort antibiotics 
such as carbapenems as well as an increase in cephalosporins. For the Namibian public sector 
the consumption in the class containing carbapenems and cephalosporins  which is the class 
called other beta-lactam antibiotics showed a 40% increase in consumption from 2010 to 2016 
from a low level. This increase in last line of defence would mean fewer options for severly ill 
patients This increase has been attributed to rising in resistance to penicillins and quinolones 
which are now being replaced by cephalosporins in countries like India (Klein, et al., 2018). 
One would need to do more in terms of resistance mapping in order to determine if this is the 
cause of the shift in the Namibia situation. If we can get this local resistance data we will then 
have sceintific basis (Klein, et al., 2018) for efforts towards reducing the consumption.  
 
5.4 National consumption trends for selected antibiotics by volume 
In the sulphonamide and trimethoprim class the co-trimoxazole 80 + 400 mg tablets were the 
highest consumed item during the period under review. This implies that co-trimoxazole 80 + 
400 mg tablets is the highest consumed antibiotic formulation in the Namibian public sector 
even outside its class. This is to be expected as these were the formulation of choice for 
prophylaxis for opportunistic infections in HIV positive patients in Namibia, given the 
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prevalence of HIV (14% in adults age 15 to 49) in Namibia during the period under review 
(MoHSS Namibia, 2013). 
 
In the beta lactam, penicillin antibiotic class the highest consumed antibiotic was amoxicillin 
which was responsible for about 70% of the beta lactam, penicillin antibiotics consumed in the 
Namibia public sector. Amoxicillin and is indicated for the treatment of a wide variety of 
conditions (Joint Formulary, 2015; MoHSS, 2011). It is therefore acceptable for it to be the 
highest consumed medicine in its class. What the data can’t tell us is if this use is rational. For 
us to find out if the use of amoxicillin is in line with guidelines is outside the scope of this 
study. 
 
The study also found that in 2012 when there was a reduction in the consumption of 
amoxicillin, there was a compensatory increase in the consumption of the other beta lactam 
penicillins ampicillin and cloxacillin. One can assume that there might have been a stock out 
of amoxicillin which lead to substitution with the other broad spectrum antibiotics within the 
same class, since the consumption pattern was reversed again in 2013 and onwards. 
 
5.5 Regional trends of antibiotic consumption by total volume 
The study found substantial variation in regional antibiotic consumption trends. The lowest 
consumption was in Ohangwena region which contributed 6% to the total national 
consumption, with Zambezi having the highest regional consumption making up about 13% of 
total consumption, more than double that of Ohangwena. The reasons for these variances were 
outside the scope of this study but need to be investigated. 
 
The regions Karas, Kavango, Oshikoto, Hardap, Erongo and Zambezi had a higher 
consumption than the national average for most of the period under review. These regions are 
spread out all over the country with no obvious similarities. Figure 1 tells us that Khomas, 
Kavango and Ohangwena had the highest population figures for the period under review. In 
2016, 14% of the national antibiotic consumption was attributable to Zambezi region which 
according to Table 1 only accommodated 3.9% of the national population in the same year. 
One would have expected that Khomas region have the highest consumption since that is where 
urbanization is high and where people are living in the poorest of conditions on the outskirts 
of the city. 
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The largest increase in consumption within the regions was in Zambezi region which increased 
by 73% from 2010 to 2016, this increase was followed by a 57% increase in Ohangwena region 
and a 47% increase in Omaheke. These large increases would need to be investigated further 
in order to determine whether the increases were appropriate and if not to recommend 
appropriate action. 
 
5.6 Regional consumption by antibiotic class 
The beta lactam antibiotics, penicillin class and sulphonamide and trimethoprim antibiotics 
were the highest consumed classes across all the different regions. For the Zambezi region, 
which is the region with the highest consumption, the above classes were closely followed by 
an increasing consumption in macrolides, lincosamides and streptogramins, as well as the 
tetracycline classes of antibiotics.   
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS  
 
6.1 Conclusion  
This study described the patterns of antibiotic consumption in the Namibian public health 
sector over seven years between 2010 and 2016 by region, antibiotic class and antibiotic. It has 
provided trend and regional data that can serve as a baseline for the Namibian AMR 
stewardship program. The total national antibiotic consumption for Namibia, 38.31 DID in 
2010 and 43.37 DID in 2016, is classified as high according to the European Surveillance of 
Antimicrobial Consumption (ESAC) 2010 classification system.  
 
When looking at consumption at the regional level, Karas, Kavango, Oshikoto, Hardap, Erongo 
and Zambezi regions contributed significantly to the national consumption. The largest 
increase in consumption within the regions was for Zambezi region which increased by 73% 
from 2010 to 2016; this increase was followed by an increase of 57% in the Ohangwena region 
and a 47% increase in the Omaheke region. These large increases would need to be investigated 
further in order to determine whether the increases were appropriate and if not appropriate 
actions should be recommended. 
 
The study found that the highest class of antibiotics consumed in Namibia were sulphonamides 
and trimethoprim, which contributed 51% of the total consumption in 2016 followed by beta 
lactam penicillins responsible for 32% of consumption. The high consumption of 
sulphonamides and trimethoprim could be attributed to the use of co-trimoxazole prophylaxis 
for HIV/AIDS related opportunistic infections. It is therefore imperative that one of the 
consumption reduction strategies should be targeted at reducing the burden of HIV/AIDS with 
the aim of reducing the requirement for the antibiotic co-trimoxazole (Klein, et al., 2018).The 
high consumption of beta lactam penicillins class is ascribed to the fact that beta lactam 
penicillins are first line treatment in the majority of the cases needing antibiotics in Namibia 
according to the national STGs (MoHSS, 2011). 
 
The important data gathered during this study could serve as baseline data for monitoring and 
measuring the impact of Namibia’s recently finalized National Action Plan on Antimicrobial 
Resistance (Namibia MoHSS, 2017). It could also serve as baseline data for different 
interventions to be developed and implemented through the newly revived antimicrobial 
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stewardship program. While some of these interventions may be national others could be 
targeted at high volume consuming regions or randomized regions to learn which interventions 
are effective. Such an approach of testing interventions would allow the AMR stewardship 
committee to learn which interventions were most effective in the Namibian context. 
 
In conclusion, this study has highlighted some of the key problem areas in antimicrobial use, 
including areas for further investigation, which can guide future interventions. Regular 
monitoring of consumption is important and annual updates of the consumption data for 2017 
and 2018 should be under taken early in 2019. 
 
6.2. Recommendations  
The following recommendations are proposed: 
 
1. This study should be carried out on an annual basis by each Regional Pharmacist in 
each region in Namibia. The differences in consumption rates between regions should 
be further investigated in order to determine the cause of the differences. The discussion 
of the results should be a standing agenda point at the Annual National Pharmacists’ 
Forum. The main aim would be to assist in devising interventions towards 
rationalization of antibiotic use and for sharing best practices from the regions that are 
performing better than others. Regular monitoring and evaluation of the 
implementation of the devised interventions would also be required in order to ensure 
that they are efficient and effective. 
 
2. All countries should use this methodology to determine the consumption of antibiotics 
in their countries. This would increase the pool of data on the consumption of antibiotics 
in order to enable benchmarking. 
 
3. In future, primary consumption data should be used for assessing antibiotic use. This is 
to avoid having to assume that all medicines issued to the facilities are consumed and 
not take into account that losses occur from expiries, theft as well as breakage, as is the 
case when secondary data is used. This data is already available for the private sector 
and will be possible in Namibia in the near future as MoHSS is working on an electronic 
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dispensing tool which will enable the country to collect this data for the public sector 
as well. 
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Appendix 1: CMS Distribution Network. 
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Appendix 2: NEMList Classification according to level of availability and prescribing restrictions 
 
ABC The preparation can be ordered and prescribed at all levels of care by any competent prescriber.  
ABC# The treatment must be initiated by a Medical Officer, but the preparation can be available at health centres 
and clinics for follow-up treatment of chronic patients only.  
ABC-R The preparation will be available at PHC facilities to be used ONLY according to conditions specified in 
the NEMList. The inventory of these medicines must be controlled with the appropriate registers 
AB The preparation will be available for prescription by any Medical Officer and for ordering at district 
hospital (Class C) or higher levels 
AB* As for AB but the preparation will also be available at clinics and health centres conducting deliveries. 
A The preparation will be available for ordering and prescription at regional hospitals (Class B) or higher 
levels 
S The preparation will be available for prescription by designated Specialists only 
R The preparation will be available for use ONLY for specific conditions and/or in restricted circumstances, 
as specified in Chapter 2 of this document.  
IMAI-R These items are to be made available at clinics and health centres that have staff that have been trained in 
IMAI. Refer to Chapter 2 for more details They can also be stocked at District Hospital levels and above, 
and used as normal AB class items in these facilities 
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Appendix 3: List of General Anti-infectives (excerpt from MoHSS (2016)) 
 
G    GENERAL ANTI - INFECTIVES. SYSTEMIC  
   
            
  Cephalosporins         
 MEDICINE  STRENGTH DOSAGE FORM  LEVEL VEN 
021 Cefazolin 1 gram Powder for 
Injection 
AB 
E 
061 Cefixime 200mg Tablets R V 
051 Cefradine 500mg Capsules AB E 
061 Cefradine 125mg/5ml Suspension A E 
021 Ceftriaxone 250mg Powder for 
Injection 
R 
V 
021 Ceftriaxone 1g Powder for 
Injection 
A 
E 
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021 Cefuroxime 750mg Powder for 
Injection 
AB 
E 
051 Cefuroxime 250mg Tablets AB E 
061 Cefuroxime 125mg/5ml Suspension AB E 
            
  Penicillins          
061 Amoxycillin 125mg/5ml Syrup ABC V 
051 Amoxycillin 250mg Capsules ABC V 
061 Amoxycillin + Clavulanic Acid  125mg/31mg Suspension  AB E 
  Amoxycillin + Clavulanic Acid  1000/200 mg Injection AB V 
051 Amoxycillin + Clavulanic Acid  875/125mg Tablets AB E 
021 Ampicillin 250mg Powder for 
Injection 
AB 
V 
021 Ampicillin 500mg Powder for 
Injection 
AB 
V 
021 Benzathine Benzylpenicillin 2.4 million IU Powder for 
Injection 
ABC 
V 
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021 Benzyl-, + Benzathine + Procaine 
Penicillin 
1.2 million IU Powder for 
Injection 
ABC 
N 
021 Benzylpenicillin 1 million IU Powder for 
Injection 
AB 
E 
051 Cloxacillin 250mg Capsules AB E 
061 Cloxacillin 125mg/5ml Syrup AB E 
021 Cloxacillin 250mg Powder for 
Injection 
AB 
E 
021 Cloxacillin 500mg Powder for 
Injection 
AB 
E 
051 Phenoxymethylpenicillin  250mg Tablets ABC V 
061 Phenoxymethylpenicillin  250mg/5ml Syrup ABC V 
021 Piperacillin + Tazobactam 4g + 500mg Powder for 
Injection 
S 
E 
021 Procaine Benzyl Penicillin 3g (3 million IU) or 300mg/ml Powder for 
Injection  (10ml) 
ABC 
V 
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  All other Antibiotics          
021 Amikacin 250mg/ml Injection (2ml) A V 
051 Azithromycin 1g Tablets ABC V 
061 Azithromycin 200mg/5ml Suspension ABC V 
051 Chloramphenicol 250mg Capsules AB E 
061 Chloramphenicol 125mg/5ml Suspension AB E 
021 Chloramphenicol 1g Powder for 
Injection 
AB 
E 
051 Ciprofloxacin 500mg Tablets R V 
021 Ciprofloxacin 2mg/ml Infusion (200ml) R V 
051 Clindamycin 150mg Capsules A E 
021 Clindamycin 150mg/ml Injection (4ml) S E 
051 Doxycycline 100mg Capsules ABC V 
061 Erythromycin 125mg/5ml Suspension R E 
051 Erythromycin 250mg Tablets ABC V 
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021 Erythromycin 1g Powder for 
Injection 
A 
E 
051 Fusidic Acid 250mg Capsules AB N 
061 Fusidic Acid 250mg/5ml Syrup S N 
021 Fusidic Acid 500mg Powder for 
Injection 
S 
E 
021 Gentamicin 10mg/ml Injection (2ml) AB V 
021 Gentamicin 40mg/ml Injection (2ml) AB V 
051 Hydroxychloroquine 200mg Tablets AB E 
021 Linezolid 2mg/ml Infusion (300ml) R V 
051 Linezolid 400mg Tablets R V 
051 Linezolid 600mg Tablets R V 
021 Meropenem 500mg Injection S V 
021 Meropenem 1g Injection S V 
051 Nalidixic Acid 500mg Tablets ABC V 
061 Nalidixic Acid 250mg/5ml Suspension ABC V 
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051 Nitrofurantoin 100mg Capsules AB E 
021 Streptomycin 1g Powder for 
Injection 
ABC# 
V 
021 Vancomycin 500mg Injection S V 
021 Vancomycin 1g Injection S V 
            
  Systemic Antimycotics excluding Griseofulvin        
041 Amphotericin B 50mg Powder for 
Injection 
AB 
V 
021 Fluconazole 2mg/ml Solution for 
Infusion 
R 
N 
051 Fluconazole 200mg Tablets R E 
051 Itraconazole 100mg Capsules AB E 
051 Ketoconazole 200mg Tablets A E 
021 Voriconazole 200mg/ml Injection R E 
            
  Sulphonamides with Anti-Infectives in Combination        
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051 Co-trimoxazole 80mg/400mg Tablets ABC E 
061 Co-trimoxazole 40mg/200mg/5ml Suspension ABC E 
021 Co-trimoxazole 80mg/400mg/5ml Injection AB E 
051 Metronidazole 400mg Tablets ABC V 
061 Metronidazole 200mg/5ml Syrup ABC E 
052 Metronidazole 1g Suppositories AB E 
021 Metronidazole 5mg/ml Injection (100ml) S V 
            
  Tuberculostatics, excluding Streptomycin        
051 Bedaquiline 100mg Tablets R V 
021 Capreomycin 1g Injection S V 
021 Cefoxitin 100mg Injection S V 
051 Clarithromycin 500mg Tablets S V 
051 Cycloserine 250mg Tablets AB V 
051 Delamanid 50mg Tablets R V 
051 Ethambutol 100mg Tablets ABC# V 
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051 Ethambutol 400mg Tablets ABC# V 
051 Ethionamide 250mg Tablets AB V 
051 Isoniazid  100mg Tablets ABC# V 
021 Kanamycin 1g Injection AB V 
051 Levofloxacin 250mg Tablets AB V 
051 Moxifloxacin 400mg Tablets R V 
021 Moxifloxacin 400mg/250ml Infusion S V 
001 p-Amino Salicylic Acid 4g Sachet S V 
051 Pyrazinamide 500mg Tablets ABC# V 
051 Rifampicin 150mg Capsules  ABC# V 
051 Rifampicin 450mg Tablets ABC# V 
061 Rifampicin 100mg/5ml Syrup ABC# V 
061 Rifampicin + Isoniazid 60mg +30mg Tablets ABC# V 
061 Rifampicin + Isoniazid 150mg +75mg Tablets ABC V 
061 Rifampicin + Isoniazid + 
Pyrazinamide 
60mg +30mg +150mg Tablets ABC# 
V 
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061 Rifampicin + Isoniazid + Ethambutol 150mg + 75mg + 275mg  Tablets ABC# V 
061 Rifampicin + Isoniazid + 
Pyrazinamide + Ethambutol 
150mg + 75mg + 400mg + 275mg  Tablets ABC 
V 
            
  Leprostatics          
051 Clofazimine 100mg Tablets A V 
051 Dapsone 100mg Tablets A V 
051 Rifampicin 450 mg Tablets ABC# V 
            
  Antivirals for Systemic Use         
051 Acyclovir (Aciclovir) 400mg Tablets R E 
051 Acyclovir (Aciclovir) 800mg Tablets R E 
  
    
 
  Antiretrovirals         
012 Abacavir 300mg Tablets AB V 
012 Abacavir 20mg/ml Liquid AB V 
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012 Abacavir 60mg  Tablets AB V 
012 Didanosine 025mg Capsules/Tablets AB V 
012 Didanosine 050mg Capsules/Tablets AB V 
012 Didanosine 100mg Capsules/Tablets AB V 
012 Didanosine 200mg Capsules/Tablets AB V 
012 Didanosine 250mg Capsules/Tablets AB V 
012 Didanosine 400mg Capsules/Tablets AB V 
012 Efavirenz 050mg Capsules/Tablets AB V 
012 Efavirenz 100mg Capsules/Tablets AB V 
012 Efavirenz 200mg Capsules/Tablets AB V 
012 Efavirenz 600mg Tablets IMAI-R V 
012 Efavirenz 30mg/ml Syrup AB V 
012 Indinavir  400mg Capsules AB V 
012 Lamivudine 50mg/5ml Oral Solution AB V 
012 Lamivudine 150mg Tablets IMAI-R V 
012 Lamivudine + Abacavir  30mg + 60mg  Tablets AB V 
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012 Lamivudine + Stavudine 030mg + 06mg Tablets AB V 
012 Lamivudine + Stavudine 060mg + 12mg Tablets AB V 
012 Lamivudine + Stavudine 150mg + 30mg Tablets IMAI-R V 
012 Lamivudine + Stavudine + Abacavir 150mg + 300mg + 300mg Tablets IMAI-R V 
012 Lamivudine + Stavudine + 
Nevirapine 
030mg + 06mg + 050mg Tablets AB 
V 
012 Lamivudine + Stavudine + 
Nevirapine 
060mg + 12mg + 100mg Tablets AB 
V 
012 Lamivudine + Stavudine + 
Nevirapine 
150mg + 30mg + 200mg Tablets IMAI-R 
V 
012 Lamivudine + Tenofovir 300mg + 300mg Tablets IMAI-R V 
012 Lamivudine + Zidovudine 30mg + 60mg  Tablets AB V 
012 Lamivudine + Zidovudine 150mg + 300mg Tablets IMAI-R V 
012 Lamivudine + Zidovudine + 
Nevirapine 
150mg + 300mg + 200mg Tablets IMAI-R 
V 
012 Lamivudine + Zidovudine + 
Nevirapine 
30mg + 60mg + 50mg Tablets AB 
V 
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012 Lopinavir + Ritonavir (400 + 100)mg/5ml Oral Solution AB V 
012 Lopinavir + Ritonavir 200mg + 50mg Tablets AB V 
012 Lopinavir + Ritonavir 100mg + 25mg Tablets AB V 
012 Nevirapine 200mg Tablets IMAI-R V 
012 Nevirapine 50mg/5ml Suspension AB V 
012 Ritonavir 100mg Capsules AB V 
012 Stavudine 15mg Capsules AB V 
012 Stavudine 20mg Capsules AB V 
012 Stavudine 30mg Capsules AB V 
012 Stavudine 1mg/ml Liquid AB V 
012 Tenofovir 300mg Tablets IMAI-R V 
012 Tenofovir + Emtricitabine 300mg+200mg Tablets IMAI-R V 
012 Tenofovir + Emtricitabine + 
Efavirenz  
300mg+200mg+600mg Tablets IMAI-R 
V 
012 Zidovudine 50mg/5ml Syrup AB V 
012 Zidovudine 100mg Tablets AB V 
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012 Zidovudine 300mg Tablets IMAI-R V 
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Appendix 4: Unique list of items  
 
  ATC 1st level ATC 2nd 
level 
ATC 5th 
level 
DD
D in 
gra
ms 
Adm.R
oute 
ATC 3rd level ATC4thlevel item description pack size strength 
1 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01AA02 0.1 O Tetracyclines  Tetracyclines  Doxycycline 100mg 
tabs 
100 100 
2 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01AA02 0.1 O Tetracyclines  Tetracyclines  Doxycycline 100mg 
tabs 
1000 100 
3 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01AA06 1 O Tetracyclines  Tetracyclines  Oxytetracycline 
250mg caps 
1000 250 
4 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01BA01 3 P Amphenicols  Amphenicols  Chloramphenicol 
1gm inj 
50 1000 
5 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01BA01 3 O Amphenicols  Amphenicols  Chloramphenicol 
250mg caps 
1000 250 
6 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01BA01 3 O Amphenicols  Amphenicols  Chloramphenicol 
125mg/5ml susp 
20 125 
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7 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01BA01 3 P Amphenicols  Amphenicols  Chloramphenicol 
1gm inj  
1 1000 
8 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 500mg pfi 5 500 
9 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 500mg pfi 50 500 
10 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 250mg pfi 5 250 
11 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 500mg pfi 100 500 
12 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 250mg pfi 50 250 
13 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 500mg pfi 10 500 
http://etd.uwc.ac.za/
68 
 
14 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 250mg pfi 10 250 
15 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA01 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Ampicillin 250mg pfi 100 250 
16 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA12 14 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Piperacillin/tazobacta
m pfi 
1 4500 
17 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA12 14 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Piperacillin/tazobacta
m pfi 
12 4500 
18 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE08 3.6 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Benzathine penicillin 
2.4mu 
50 1500 
19 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE08 3.6 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Benzathine penicillin 
2.4mu 
10 1500 
20 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE09 0.6 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Procaine penicillin g 
3miu inj 
50 3000 
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21 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE09 0.6 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Procaine penicillin g 
3miu inj 
10 3000 
22 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 250mg pfi 10 250 
23 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 250mg pfi 50 250 
24 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 500mg pfi 10 500 
25 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 500mg pfi 50 500 
26 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 O beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 250mg 
caps 
100 250 
27 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 O beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 
125mg/5ml syr 
20 125 
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28 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 O beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 250mg 
caps 
1000 250 
29 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CF02 2 O beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Cloxacillin 250mg 
caps 
500 250 
30 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DB04 3 P first-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefazoline 1g inj 1 1000 
31 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DB04 3 P first-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefazoline 500mg inj 1 500 
32 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DB09 2 O first-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefradine 125mg/5ml 
suspn 
20 125 
33 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DB09 2 O first-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefradine 500mg 
caps 
100 500 
34 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DB09 2 O first-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefradine 500mg 
caps 
20 500 
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35 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC01 6 P second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefoxitin 1g inj 50 1000 
36 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC01 6 P second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefoxitin 1g inj 1 1000 
37 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC02 3 P second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefuroxime 750mg 
pfi 
1 750 
38 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC02 3 P second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefuroxime 750mg 
pfi 
50 750 
39 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC02 0.5 O second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefuroxime 
250mgtabs 
10 250 
40 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC02 0.5 O second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefuroxime 
125mg/5ml suspn 
20 125 
41 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC02 0.5 O second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefuroxime tabs 
250mg 
100 250 
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42 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DC02 3 P second-
generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefuroxime 750mg 
pfi 
10 750 
43 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DD02 4 P third-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Ceftazidime 1g inj 1 1000 
44 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DD04 2 P third-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Ceftriaxone 250mg 
pfi 
1 250 
45 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DD04 2 P third-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Ceftriaxone 1gm pfi 1 1000 
46 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DD08 0.4 O third-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefixime 200mg tabs 100 200 
47 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DD08 0.4 O third-generation 
cephalosporins 
other beta-
lactam 
antibacterials 
Cefixime 200mg tabs 20 200 
48 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DH02 2 P carbapenems other beta-
lactam 
antibacterials 
Meropenem 1g inj 1 1000 
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49 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DH02 2 P carbapenems other beta-
lactam 
antibacterials 
Meropenem 500mg 
inj 
1 500 
50 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DH51 2 P carbapenems other beta-
lactam 
antibacterials 
Imipenem 500 mg + 
cilastatin 
1 500 
51 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01DH51 2 P carbapenems other beta-
lactam 
antibacterials 
Imipenem 500mg inj 1 500 
52 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
80+400mg tabs 
500 480 
53 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
80+400mg tabs 
100 480 
54 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
80+400mg tabs 
1000 480 
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55 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 3.36 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
40/200mg/5ml 
20 240 
56 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 3.36 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
40/200mg/5ml 
20 240 
57 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 P combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
80mg/400mg inj 
10 480 
58 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
160+800mg tabs 
500 960 
59 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 O combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
80+400mg tabs 
1000 480 
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60 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01EE01 1.92 P combinations of 
sulfonamides and 
trimethoprim, 
incl. derivatives 
sulfonamides 
and 
trimethoprim 
Co-trimoxazole 
80mg/400mg inj 
5 480 
61 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA01 1 O macrolides macrolides, 
lincosamides 
and 
streptogramins 
Erythromycin 250mg 
tabs 
100 250 
62 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA01 1 P macrolides macrolides, 
lincosamides 
and 
streptogramins 
Erythromycin 1g pfi 1 1000 
63 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA01 1 O macrolides macrolides, 
lincosamides 
and 
streptogramins 
Erythromycin 
125mg/5ml suspn 
20 125 
64 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA09 0.5 O macrolides macrolides, 
lincosamides 
and 
streptogramins 
Clarithromycin 
500mg tabs 
14 500 
65 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA10 0.3 O macrolides macrolides, 
lincosamides 
Azithromycin 500mg 
tabs 
3 500 
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and 
streptogramins 
66 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA10 0.3 O macrolides macrolides, 
lincosamides 
and 
streptogramins 
Azithromycin 
200mg/5ml suspn 
20 200 
67 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FA10 0.3 O macrolides macrolides, 
lincosamides 
and 
streptogramins 
Azithromycin 
1000mg tabs 
30 1000 
68 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FF01 1.2 O lincosamides macrolides, 
lincosamides 
and 
streptogramins 
Clindamycin 150mg 
caps 
100 150 
69 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FF01 1.8 P lincosamides macrolides, 
lincosamides 
and 
streptogramins 
Clindamycin 
150mg/ml inj 4ml 
1 600 
70 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01FF01 1.8 P lincosamides macrolides, 
lincosamides 
and 
streptogramins 
Clindamycin 
150mg/ml inj 4ml 
10 600 
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71 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GA01 1 P streptomycins aminoglycoside 
antibacterials 
Streptomycin 
sulphate 1gm pfi 
50 1000 
72 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB04 1 P other 
aminoglycosides 
aminoglycoside 
antibacterials 
Kanamycin 1g inj 50 1000 
73 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB04 1 P other 
aminoglycosides 
aminoglycoside 
antibacterials 
Kanamycin 1g inj 10 1000 
74 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB06 1 P other 
aminoglycosides 
aminoglycoside 
antibacterials 
Amikacin 250mg/ml 
inj 2ml 
10 500 
75 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB06 1 P other 
aminoglycosides 
aminoglycoside 
antibacterials 
Amikacin 250mg/ml 
inj 2ml 
1 250 
76 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA01 0.4 O fluoroquinolones quinolone 
antibacterials 
Ofloxacin 400mg tabs 1000 400 
77 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA02 1 O fluoroquinolones quinolone 
antibacterials 
Ciprofloxacin 500mg 
tabs 
10 500 
78 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA02 1 O fluoroquinolones quinolone 
antibacterials 
Ciprofloxacin 
2mg/ml 200ml 
1 400 
79 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA02 1 O fluoroquinolones quinolone 
antibacterials 
Ciprofloxacin 500mg 
tabs 
10 500 
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80 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA02 1 O fluoroquinolones quinolone 
antibacterials 
Ciprofloxacin 
250mg/5ml susp 
20 250 
81 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA12 0.5 O fluoroquinolones quinolone 
antibacterials 
Levofloxacin 250mg 
tabs 
672 250 
82 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA12 0.5 O fluoroquinolones quinolone 
antibacterials 
Levofloxaciin 250mg 
tabs 
100 250 
83 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA12 0.5 O fluoroquinolones quinolone 
antibacterials 
Levofloxacin 500mg 
tabs 
5 500 
84 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA12 0.5 O fluoroquinolones quinolone 
antibacterials 
Levofloxacin 500mg 
tabs 
10 500 
85 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA12 0.5 O fluoroquinolones quinolone 
antibacterials 
Levofloxacin 250mg 
tabs 
5 250 
86 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA12 0.5 O fluoroquinolones quinolone 
antibacterials 
Levofloxacin 250mg 
tabs 
50 250 
87 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA14 0.4 O fluoroquinolones quinolone 
antibacterials 
Moxifloxacin 400mg 
tabs 
5 400 
88 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MA14 0.4 O fluoroquinolones quinolone 
antibacterials 
Moxifloxacin 
400mg/250ml inj 
1 400 
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89 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MB02 4 O other quinolones quinolone 
antibacterials 
Nalidixic acid 500mg 
tabs 
100 500 
90 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MB02 4 O other quinolones quinolone 
antibacterials 
Nalidixic acid 
250mg/5ml suspn 
20 250 
91 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01MB02 4 O other quinolones quinolone 
antibacterials 
Nalidixic acid 500mg 
tabs 
1000 500 
92 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XA01 2 P glycopeptide 
antibacterials 
other 
antibacterials 
Vancomycin hcl 
500mg pfi 
10 500 
93 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XA01 2 P glycopeptide 
antibacterials 
other 
antibacterials 
Vancomycin hcl 1g 
pfi 
10 1000 
94 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XA02 0.4 P glycopeptide 
antibacterials 
other 
antibacterials 
Teicoplanin 400mg 
inj 
1 400 
95 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XC01 1.5 P steroid 
antibacterials 
other 
antibacterials 
Fusidic acid 500mg 
pfi 
1 500 
96 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XC01 1.5 O steroid 
antibacterials 
other 
antibacterials 
Fusidic acid 
250mg/5ml suspn 
20 500 
97 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XE01 0.2 O nitrofuran 
derivatives 
other 
antibacterials 
Nitrofurantoin 100mg 
caps 
250 100 
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98 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XE01 0.2 O nitrofuran 
derivatives 
other 
antibacterials 
Nitrofurantoin 100mg 
caps 
1000 100 
99 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XE01 0.2 O nitrofuran 
derivatives 
other 
antibacterials 
Nitrofurantoin 100mg 
caps 
50 100 
100 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XE01 0.2 O nitrofuran 
derivatives 
other 
antibacterials 
Nitrofurantoin 100mg 
caps 
30 100 
101 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XX08 1.2 P other 
antibacterials 
other 
antibacterials 
Linezolid 
600mg/300ml 
infusion 
1 600 
102 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XX08 1.2 P other 
antibacterials 
other 
antibacterials 
Linezolid 
600mg/300ml iv infus 
10 600 
103 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XX08 1.2 O other 
antibacterials 
other 
antibacterials 
Linezolid 600mg tabs 10 600 
104 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01XX08 1.2 O other 
antibacterials 
other 
antibacterials 
Linezolid 400mg tabs 10 400 
105 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE01 3.6 P  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Benzyl penicillin g 
5mu pfi 
50 5000 
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106 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE01 3.6 P  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Benzyl penicillin g 
1mu pfi 
50 1000 
107 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE01 3.6 P  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Benzyl penicillin g 
1mu pfi 
100 1000 
108 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB03 0.24 P  other 
aminoglycosides 
aminoglycoside 
antibacterials 
Gentamycin 40mg/ml 
inj 2ml 
10 80 
109 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB03 0.24 P  other 
aminoglycosides 
aminoglycoside 
antibacterials 
Gentamycin 10mg/ml 
inj 2ml 
10 20 
110 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB03 0.24 P  other 
aminoglycosides 
aminoglycoside 
antibacterials 
Gentamycin 10mg/ml 
inj 2ml 
100 20 
111 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01GB03 0.24 P  other 
aminoglycosides 
aminoglycoside 
antibacterials 
Gentamycin 40mg/ml 
inj 2ml 
100 80 
112 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA04 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 250mg 
caps 
100 250 
113 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA04 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 250mg 
caps 
500 250 
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114 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CR02 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 
875mg+clavulanic 
10 875 
115 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA04 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 
125mg/5ml suspn 
20 125 
116 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA04 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 250mg 
caps 
1000 250 
117 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CR02 3 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 500mg + 
clavulanic 
5 500 
118 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CR02 3 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 1000mg 
+clavulanic 
5 1000 
119 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA04 3 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 500mg + 
clavulanic 
10 500 
120 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CA04 3 P beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 1000mg 
+clavulanic 
10 1000 
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121 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CR02 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 875mg + 
clavulanic 
10 875 
122 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CR02 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 250mg + 
clavulanic 
15 250 
123 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CR02 1 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Amoxycillin 125mg + 
clavulanic 
20 125 
124 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE02 2 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Pen v k 250mg tabs 500 250 
125 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE02 2 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Pen v k 250mg tabs 1000 250 
126 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE02 2 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Pen v k 250mg/5ml 
suspn 
20 250 
127 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE02 2 O  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Pen v k 125mg/5ml 
suspn 
20 125 
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128 Anti-infectives 
for systemic use 
Antibacterial 
drugs 
J01CE01 3.6 P  beta-lactam 
antibacterials, 
penicillins 
beta-lactam 
antibacterials, 
penicillins 
Penicillin 1.2miu pfi 50 750 
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Appendix 5: Data Collection Tool 
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Appendix 6: Ethical clearance from the University of the Western Cape Biomedical Research Ethics Committee & 
permission for access and use of the data for the study provided by MoHSS 
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Appendix 7: National antibiotic consumption trends per antibiotic classification 
 
 
 
National antibiotic consumption trends per antibiotic classification, Erongo, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Hardap, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Karas, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Kavango, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Khomas, 2010-2016 
0,00
5,00
10,00
15,00
20,00
25,00
30,00
2010 2011 2012 2013 2014 2015 2016
D
ID
Year
Amphenicols Beta lactam antibiotics, penicillins Macrolides, lincosamides and streptogramins
Other antibacterials Other beta lactam antibacterials Quinolone antibacterials
Sulphonamides and trimethoprim Tetracyclines Aminoglycoside antibacterials
http://etd.uwc.ac.za/
94 
 
 
 
National antibiotic consumption trends per antibiotic classification, Kunene, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Ohangwena, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Omaheke, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Omusati, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Oshana, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Oshikoto, 2010-2016 
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National antibiotic consumption trends per antibiotic classification, Otjozondjupa, 2010-2016 
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Appendix 8: Antibiotic consumption by region by antibiotic classification 
 
 
 
Antibiotic consumption by region by antibiotic classification, Namibia, 2011 
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Antibiotic consumption by region by antibiotic classification, Namibia, 2012 
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Antibiotic consumption by region by antibiotic classification, Namibia, 2013 
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Antibiotic consumption by region by antibiotic classification, Namibia, 2014 
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Antibiotic consumption by region by antibiotic classification, Namibia, 2015 
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